clinical_trial_study_id,clinical_trial_sponsor,clinical_trial_phase,location_continent,study_eligibility_standard_age_list,outcome_overview_time_frame,outcome_overview_assay,outcome_overview_dose_number,outcome_overview_serotype,outcome_overview_value,outcome_overview_upper_limit,outcome_overview_lower_limit,outcome_overview_vaccine,outcome_overview_dose_description,outcome_overview_schedule,outcome_overview_time_frame_weeks
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,23F,0.29,0.34,0.25,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,23F,0.43,0.48,0.39,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,19A,0.66,0.78,0.55,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,7F,0.49,0.55,0.44,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,1,0.18,0.21,0.16,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,14,0.71,0.85,0.59,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,1,0.3,0.32,0.28,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,14,0.99,1.1,0.89,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,9V,0.38,0.42,0.35,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,6B,0.62,0.71,0.55,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,5,0.4,0.44,0.37,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,6A,0.73,0.8,0.67,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,19A,0.91,1.01,0.81,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,6A,0.31,0.36,0.26,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,9V,0.41,0.46,0.36,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,19F,1.35,1.55,1.17,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,5,0.34,0.39,0.29,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,19F,0.82,0.92,0.73,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,7F,0.64,0.69,0.59,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,GMC,4,6B,0.9,0.97,0.84,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,7F,1851.8,2740.5,1251.3,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,7F,1765.9,2518.8,1238.1,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,5,31.6,50.1,20,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,23F,91.6,155.3,54,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,1,8.7,12.9,5.9,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,19A,17.6,28.3,11,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,14,215.1,366.6,126.2,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,1,11,15.1,8,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,19F,133.5,261.1,68.2,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,19A,89.7,160.3,50.2,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,9V,114.5,205.5,63.8,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,6B,31.1,47.2,20.5,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,6B,116.3,180.6,74.9,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,19F,139.8,249.8,78.3,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,5,41.4,62,27.6,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,6A,118.1,226.5,61.6,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,23F,393.8,707.4,219.3,PCV10 (Pneumosil),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,9V,158.2,289.9,86.3,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,14,193.4,346.6,107.9,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",One year post booster vaccination,OPA,4,6A,8.3,13.6,5,PCV10 (Synflorix),12m post boost child,3+1 child,96
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,9V,1229,1542,979.3,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,9V,168.7,242.4,117.4,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,6A,3063,4030,2329,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,19F,1580,2099,1190,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,19A,645.6,851,489.7,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,6B,1610,2040,1271,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,19F,1592,2019,1256,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,7F,1438,1820,1136,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,6B,2897,3714,2259,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,7F,1795,2205,1461,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,14,866.8,1296,579.6,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,7F,4036,4981,3270,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,1,344.5,453.5,261.8,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,1,99.21,130.9,75.22,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,14,1254,1776,885.8,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,14,1401,2029,967.4,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,19A,53.15,84.99,33.24,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,23F,1213,1557,945.7,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,19F,669.9,841.2,533.6,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,5,112.9,146.9,86.79,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,6A,1225,1666,900,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,9V,1155,1530,871.4,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,23F,3847,4996,2962,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,6A,39.96,69.59,22.94,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,23F,211.7,315.7,142,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,1,29.76,40.78,21.73,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,5,161.2,205,126.8,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,19A,177.5,240.5,131,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,6A,6.44,8.64,4.8,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,6B,771.4,1129,527.2,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,19F,801,1028,624.1,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,9V,417,537.8,323.3,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,14,3069,4118,2287,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,5,360.6,461.2,281.9,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,5,409.9,537.8,312.4,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,23F,774.5,1020,588.3,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,19A,8.89,11.6,6.81,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,3,6B,495.2,722.1,339.6,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,7F,6977,8691,5602,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,OPA,4,1,187.2,247.4,141.6,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,9V,1.43,1.6,1.28,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,19F,6.31,7.24,5.51,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,19A,1.5,1.64,1.37,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,5,1.31,1.41,1.21,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,23F,0.94,1.11,0.8,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,19F,4.16,4.48,3.85,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,19A,3.97,4.33,3.63,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,14,4.67,5.55,2.92,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,6A,0.42,0.5,0.36,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,23F,4.11,4.5,3.75,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,6A,4.86,5.38,4.4,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,7F,2.49,2.79,2.22,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,7F,6.36,6.89,5.87,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,14,3.86,4.57,3.25,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,7F,3.12,3.37,2.89,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,6B,1.29,1.48,1.13,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,1,2.47,2.8,2.19,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,6B,1.15,1.41,0.94,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,6B,8.32,8.99,7.7,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,19F,6.18,6.71,5.7,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,9V,1.29,1.39,1.2,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,19A,0.26,0.31,0.23,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,5,1.49,1.59,1.39,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,23F,1.65,1.8,1.5,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,5,1.26,1.38,1.14,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,14,5.06,5.62,4.57,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,19F,9.79,10.92,8.77,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,9V,2.08,2.31,1.87,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,1,2.12,2.38,1.88,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,6A,0.12,0.14,0.11,PCV10 (Synflorix),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,9V,1.8,1.94,1.67,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,7F,4.07,4.52,3.67,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,14,6.84,7.68,6.08,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,6B,4.44,4.93,4,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,1,5.71,6.21,5.25,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,6A,1.09,1.22,0.98,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,3,1,4.05,4.36,3.76,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,23F,2.15,2.44,1.9,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,19A,0.95,1.15,0.79,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03197376,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster vaccination,GMC,4,5,0.84,0.93,0.76,PCV10 (Synflorix),1m post boost child,3+1 child,40
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6A,8.84,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,14,8.66,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,3,0.73,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,3,0.86,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,1,3.91,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,7F,5.71,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,4,1.67,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6A,8.09,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19F,10.65,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,22F,4.12,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,22F,3.8,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,1,4.05,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,7F,7.11,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19A,15.45,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19A,15.81,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,14,9.82,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,18C,11.81,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,1,3.83,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,7F,5.94,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,5,4.63,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,9V,4.26,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,23F,7.38,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,4,1.79,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6B,11.46,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,4,2.18,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,9V,4.2,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6A,8.16,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19F,9.78,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,18C,14.07,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,5,3.96,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,22F,4.41,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,18C,10.66,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,23F,7.44,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6B,10.44,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,9V,4.44,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,3,0.74,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,23F,7.97,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19F,11.22,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,14,11.38,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19A,17.34,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6B,10.92,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,5,3.81,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,18C,9.58,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,4,2.38,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,9V,4.97,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,14,9.89,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,18C,12.08,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6B,7.28,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,1,5.22,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,4,1.87,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19A,16.18,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,3,0.55,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,7F,7.12,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,3,0.77,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19A,16.66,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6B,10.92,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,22F,4.1,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19F,10.25,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6A,8.38,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,23F,7.58,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,23F,6.03,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,9V,4.3,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,5,4.14,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,14,9.97,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,5,4.66,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19F,10.52,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6A,7.2,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,7F,6.19,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,22F,0.34,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,1,3.91,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,19F,1866.4,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,19A,3498.5,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,6A,6123.8,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,14,2509.6,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,1,251.6,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,23F,2133,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,6B,5362.7,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,19F,1993.2,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,3,214.4,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,22F,2617.4,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,4,1303.7,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,6B,5109.5,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,9V,1749.9,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,6A,6077.6,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,1,248.5,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,1,239.4,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,22F,2761.6,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,7F,4590.5,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,19A,3774.8,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,23F,2222.9,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,5,391.3,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,9V,1708.4,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,23F,2417.8,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,7F,4202,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,18C,3381,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,4,1074.4,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,9V,1690.6,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,7F,3757.7,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,18C,3522.4,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,3,198.3,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,3,232.2,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,18C,3880.8,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,19F,2017.8,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,14,2364.8,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,4,1073.1,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,5,389.8,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,6A,5845,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,22F,2676,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,14,2050.6,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,6B,5160.6,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,19A,3384.7,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950856,Merck Sharp & Dohme LLC,Phase 3,"Australia & Oceania,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,Europe,Europe,North America,North America,North America,North America,North America,Europe,Europe,North America,Europe,North America,North America,Europe,North America,Europe,South America,Europe,South America,North America,South America,North America,North America,North America,North America,Europe,South America,Europe,North America,Europe,Australia & Oceania,North America,South America,Australia & Oceania,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,5,461.6,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6A,7.21,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,4,1.88,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,5,5.56,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6A,7.01,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,3,0.96,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,9V,5.52,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,23F,6.13,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19A,14.6,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6B,6.19,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,4,2.62,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,22F,3.44,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19F,8.77,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19A,17.38,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,1,5.3,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,18C,8.99,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,14,9.39,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,7F,8.09,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,9V,4.77,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,22F,0.32,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19F,9.7,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,1,7.34,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,18C,10,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,23F,6.67,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,3,0.64,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,14,12.3,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,7F,6.18,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6B,8.6,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,5,4.57,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,3,216.2,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,3,135.1,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,14,2656.7,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,1,256.3,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,5,563.5,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,1,322.6,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,19A,3979.8,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,18C,2757.7,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,7F,5880.6,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,4,1125.6,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,6B,3258.2,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,4,1661.6,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,23F,2045.4,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,22F,74.6,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,18C,2583.7,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,19F,1695.1,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,9V,2232.9,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,9V,1817.3,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,14,1999.3,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,22F,2375.2,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,7F,4617.3,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,19A,3194.3,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,19F,1917.8,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,3,216.2,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,23F,1740.4,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,6A,5424.5,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,5,447.3,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,3,135.1,,,PCV13,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,6A,5407.2,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03950622,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,Asia,North America,North America,North America,Asia,Asia,North America,North America,North America,Asia,North America,North America,North America,Asia,Europe,North America,Europe,North America,North America,North America,Asia,North America,North America,North America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,6B,4011.7,,,PCV15,1m post dose 1 adult,1 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,6A,748.7,972,576.7,PCV20+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,4,149.9,190.1,118.2,PCV20+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,23F,292.6,420.5,203.6,PCV13+PCV20+PPV23,1m post dose 3 adult,3 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,19A,365.1,440,303,PCV13+PCV20,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,8,293.8,392.4,220,PCV13+PCV20+PPV23,1m post dose 3 adult,3 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,19F,217.7,281.8,168.1,PCV13+PCV20+PPV23,1m post dose 3 adult,3 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,19F,242.3,294.3,199.4,PCV13+PCV20,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,14,664.9,797.9,554.1,PCV13+PCV20,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,18C,621.2,821.3,469.9,PCV13+PCV20+PPV23,1m post dose 3 adult,3 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,8,602.9,752.8,482.9,PCV13+PCV20,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,7F,378.1,451.9,316.4,PCV20+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,1,115.3,137.9,96.3,PCV13+PCV20,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,9V,550.3,666.9,454,PCV20+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,6B,1159.4,1413.8,950.7,PCV13+PCV20,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,4,193.7,262,143.2,PCV13+PCV20+PPV23,1m post dose 3 adult,3 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,18C,551.9,684.4,445.1,PCV20+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,1,50.8,62,41.6,PCV20+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,5,87.3,104.2,73.2,PCV13+PCV20,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,6A,1085.3,1478.1,796.9,PCV13+PCV20+PPV23,1m post dose 3 adult,3 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,1,82.1,110.1,61.2,PCV13+PCV20+PPV23,1m post dose 3 adult,3 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,19F,159,192.3,131.4,PCV20+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,4,334.9,409.5,273.8,PCV13+PCV20,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,3,54.3,62.8,46.9,PCV13+PCV20,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,7F,555.4,660.9,466.8,PCV13+PCV20,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,6A,1080.9,1327.4,880.2,PCV13+PCV20,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,19A,340.6,439.2,264.1,PCV13+PCV20+PPV23,1m post dose 3 adult,3 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,3,39.3,48.2,32,PCV13+PCV20+PPV23,1m post dose 3 adult,3 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,3,31.1,36.1,26.7,PCV20+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,23F,450.2,566.4,357.8,PCV13+PCV20,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,6B,727.3,922.1,573.6,PCV20+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,5,62.8,74.9,52.7,PCV20+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,5,83.5,107.6,64.8,PCV13+PCV20+PPV23,1m post dose 3 adult,3 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,14,391.2,486.3,314.6,PCV20+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,19A,238.6,288.4,197.5,PCV20+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,9V,1085,1317.5,893.5,PCV13+PCV20,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,9V,723.4,937.6,558.1,PCV13+PCV20+PPV23,1m post dose 3 adult,3 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,23F,151.6,199.3,115.3,PCV20+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,18C,845.9,1033.1,692.5,PCV13+PCV20,1m post dose 2 adult,2 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,14,580.5,777,433.7,PCV13+PCV20+PPV23,1m post dose 3 adult,3 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,7F,345.8,431.7,277,PCV13+PCV20+PPV23,1m post dose 3 adult,3 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,6B,1033.3,1414.8,754.6,PCV13+PCV20+PPV23,1m post dose 3 adult,3 dose adult,0
NCT03835975,Pfizer,Phase 3,"North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,Europe,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,Europe,North America,North America,North America,North America","[""Older Adult""]",1 month after vaccination,OPA,1,8,211.9,261,172,PCV20+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,4,1499.7,1745.6,1288.3,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,7F,1875.7,2154.9,1632.6,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,14,2001.9,2276.5,1760.4,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,5,125.8,145.7,108.6,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,9V,4921.7,5643.2,4292.4,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,8,1624.3,1844.5,1430.4,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,19F,529.2,614.6,455.6,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,6B,4403.3,5059,3832.6,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,3,43.1,47.8,38.9,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,18C,4450.7,5188,3818.1,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,19F,549,638.3,472.2,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,6A,4654.1,5371,4033,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,3,46.8,51.8,42.3,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,7F,1865.6,2135.7,1629.7,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,1,175.1,201,152.5,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,19A,1434.4,1623,1267.8,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,6B,3907.3,4488.3,3401.4,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,1,164.6,189.3,143.1,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,4,1505.6,1751.3,1294.4,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,23F,1547.5,1849.2,1294.9,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,14,2091.2,2376.8,1839.9,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,3,47.3,52.4,42.7,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,7F,1820.6,2086.5,1588.5,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,9V,4604.1,5267.5,4024.4,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,8,1595,1813.7,1402.7,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,5,135.6,156.7,117.3,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,18C,3903.7,4563.2,3339.6,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,19A,1457.8,1650.6,1287.5,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,4,1568.2,1821.4,1350.2,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,19A,1528.1,1725.6,1353.2,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,14,2240.2,2553.5,1965.4,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,9V,5120.4,5872.7,4464.6,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,5,116.8,135.2,100.9,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,23F,1434.6,1718.1,1197.8,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,6B,4349.9,4984.1,3796.4,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,1,199.5,229.6,173.5,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,23F,1416.1,1696.1,1182.4,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,6A,3330.4,3844.6,2885.1,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,6A,3748.3,4315.4,3255.7,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,19F,524.5,610.3,450.7,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,8,1345.9,1527.6,1185.9,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03828617,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination,OPA,1,18C,4221.7,4929.2,3615.8,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,9V,1687.9,1907.3,1493.7,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,5,96.5,108.6,85.8,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,7F,1173,1306.9,1052.9,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,19F,290.4,329,256.4,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,8,502.3,569.8,442.8,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,19F,286.7,348.2,236,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,6B,1502.7,1838.5,1228.2,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,3,43.3,49.4,38,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,19A,600.3,670.6,537.5,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,23F,327.5,385.6,278.2,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,14,742.3,840.2,655.8,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,1,131.8,148.3,117.2,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,6A,997.1,1147.5,866.5,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,19A,618.4,735.5,519.9,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,4,577.9,660.6,505.5,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,18C,1355.2,1550.7,1184.3,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,18C,1805,2232.2,1459.6,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,4,633.3,780.4,513.9,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,6A,1203.9,1497.1,968.1,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,1,135.9,163.4,113.1,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,8,486.9,591.9,400.6,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,5,84.6,101.8,70.3,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,23F,549.1,708.9,425.4,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,7F,1047,1240.2,884,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,3,40.9,44.5,37.6,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,14,926.2,1126,761.8,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,9V,1725.7,2090.6,1424.4,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,6B,1199,1363.4,1054.3,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,8,508.1,575.3,448.8,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,7F,1187.2,1324.2,1064.4,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,5,96.9,109,86.2,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,6A,1022.8,1167.4,896.1,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,1,132,148.1,117.7,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,9V,1726.7,1949.7,1529.2,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,9V,6041.4,7354.9,4962.5,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,3,42.1,48.1,36.9,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,6A,3930.5,4864.4,3176,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,6B,4260,5243.1,3461.3,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,19F,654.8,796.8,538.2,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,18C,1395.3,1594.5,1220.9,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,19A,1415,1694.2,1181.8,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,6B,1250.4,1418.4,1102.3,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,7F,1872.8,2242.4,1564.2,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,4,1966.7,2418.3,1599.5,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,5,107.9,130.1,89.4,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,19A,611.3,682.3,547.8,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,14,1848.4,2255.7,1514.7,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,8,867,1059.2,709.7,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,18C,4460.5,5550.4,3584.6,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,19F,301.2,340.1,266.7,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,23F,1559.2,2012.2,1208.1,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,1,162.6,195.6,135.1,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,23F,324.5,380.1,277.1,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,3,42,45.7,38.7,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,14,772.8,872.3,684.7,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after vaccination,OPA,1,4,594.5,675.9,522.9,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,1,123.4,135.5,112.3,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,19F,265.8,294.1,240.2,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,5,91.6,100.5,83.4,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,18C,1252.6,1397,1123.1,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,7F,968.8,1058.3,887,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,7F,1129.2,1232.4,1034.7,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,3,47.8,51.2,44.7,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,1,153.8,168.8,140.2,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,19A,645.3,707.1,588.9,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,18C,1482.3,1651.5,1330.5,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,4,508.7,566.9,456.5,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,6A,889,994.1,795,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,23F,335.1,381.4,294.4,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,6B,1341.3,1488.8,1208.5,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,9V,1455.5,1608,1317.5,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,4,626.9,697.4,563.5,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,19F,333.3,368.3,301.5,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,3,40.7,43.6,38,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,5,109.7,120.3,100.1,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,9V,1567.8,1730.5,1420.5,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,19A,517.9,568,472.2,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,6A,1165.1,1301,1043.3,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,6B,1115.2,1239.8,1003.1,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,23F,276.5,315.2,242.5,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,14,746.7,820.1,679.8,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]",1 month after Vaccination 1,OPA,1,14,746.7,821.2,679,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]","1 month after Vaccination 1 in ""Cohort 1: 20vPnC/Saline""; 1 month after Vaccination 2 in ""Cohort 1: 13vPnC/PPSV23""",OPA,1,1,2007.6,2229.1,1808,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]","1 month after Vaccination 1 in ""Cohort 1: 20vPnC/Saline""; 1 month after Vaccination 2 in ""Cohort 1: 13vPnC/PPSV23""",OPA,2,8,848.1,935.2,769.1,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]","1 month after Vaccination 1 in ""Cohort 1: 20vPnC/Saline""; 1 month after Vaccination 2 in ""Cohort 1: 13vPnC/PPSV23""",OPA,1,8,465.6,513.1,422.5,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03760146,Pfizer,Phase 3,"North America,Europe,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,Europe,North America","[""Adult"",""Older Adult""]","1 month after Vaccination 1 in ""Cohort 1: 20vPnC/Saline""; 1 month after Vaccination 2 in ""Cohort 1: 13vPnC/PPSV23""",OPA,2,1,1079.9,1199.7,972.1,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,3,0.66,0.71,0.62,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,19A,12.04,13.72,10.57,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,5,3.45,3.75,3.17,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,9V,3.18,3.43,2.96,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,6B,6.79,7.49,6.15,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,19A,11.26,12.11,10.47,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,23F,4.96,5.81,4.25,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,22F,4.76,5.65,4.01,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,6B,6.04,7.19,5.08,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,14,14.59,16.85,12.64,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,1,2.91,3.12,2.71,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,4,1.33,1.44,1.23,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,7F,3.46,3.94,3.36,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,19F,9.07,9.74,8.45,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,22F,4.85,5.23,4.5,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,6A,4.25,4.69,3.84,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,4,1.77,2.02,1.55,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,1,3.42,3.87,3.02,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,18C,4.24,4.84,3.71,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,5,3.92,4.56,3.37,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,9V,3.61,4.12,3.17,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,14,14.28,15.53,13.13,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,6A,4.88,5.85,4.08,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,7F,4.07,4.68,3.54,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,3,0.68,0.76,0.61,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,23F,5.42,5.89,4.98,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,19F,8.81,10.02,7.74,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,GMC,2,18C,5.5,5.98,5.07,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,9V,3355.1,3590.1,3135.4,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,18C,5709,6113.6,5331.1,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,23F,4853.5,5270.2,4469.8,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,6A,11282.4,13097.5,9718.8,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,6B,6995.7,8123.2,6024.7,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,18C,3063.2,3475.5,2699.8,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,1,268.6,296,243.7,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,14,5228.9,5640.2,4847.6,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,19F,3266.3,3481.4,3064.4,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,5,731.1,871,613.6,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,9V,3983.7,4460.7,3557.8,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,19A,5369.9,5746.8,5017.7,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,19A,5888,6631,5228.2,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,19F,3272.7,3632.9,2948.2,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,6A,12928.8,14019,11923.4,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,5,564.8,622.2,512.7,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,23F,3887.3,4530,3335.8,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,14,5889.8,6647.8,5218.2,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,7F,5756.4,6124.6,5410.4,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,4,1416,1531.8,1308.9,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,1,267.2,323.9,220.4,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,22F,3926.5,4228.7,3645.9,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,3,150.6,173.8,130.6,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,6B,10336.9,11073.4,9649.4,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,22F,291.6,383.6,221.8,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,3,199.3,215.2,184.6,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,4,2576.1,2913.2,2278,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,OPA,1,7F,7588.9,8500.2,6775.3,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,2,22F,4060.2,4908.4,3358.6,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,2,5,626.7,738.7,531.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,1,7F,6070.5,6465.6,5699.7,PCV15,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,2,14,5317.6,6034.1,4686.1,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,1,18C,3260.6,3477.5,3057.3,PCV15,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,2,6A,5739.9,6623.1,4974.4,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,1,19F,3198.6,3397.8,3011,PCV15,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,1,14,5644.9,6055.2,5262.5,PCV15,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,2,7F,6223.9,6923,5595.3,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,2,1,214.4,254.5,180.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,2,19A,4286.4,4786.4,3838.6,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,1,9V,3133.1,3363.7,2918.4,PCV15,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,2,4,1980.6,2214.6,1771.3,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,2,19F,3085.4,3435.9,2770.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,1,6A,5810.3,6290.3,5366.9,PCV15,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,1,22F,3624,3880.3,3384.5,PCV15,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,2,6B,4412.4,5001.5,3892.8,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,2,18C,2294.4,2564.8,2052.5,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,1,23F,3057.3,3311,2823,PCV15,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,1,3,211,228.1,195.2,PCV15,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,1,6B,5215.2,5592.2,4863.6,PCV15,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,2,9V,3364.1,3807.6,2972.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,1,4,1734.5,1856.4,1620.7,PCV15,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,1,19A,4336.2,4655.6,4038.6,PCV15,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,2,3,208,240.7,179.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,2,23F,2896,3362.7,2494.1,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,1,5,595.1,650.5,544.5,PCV15,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Month 7,OPA,1,1,266.6,291.8,243.6,PCV15,1m post dose 2 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,4,2.71,3.13,2.34,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,18C,9.32,10.79,8.06,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,18C,14.57,15.81,13.42,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,4,1.53,1.66,1.4,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,14,17.35,20.16,14.93,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,7F,5.18,5.62,4.77,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,1,3.56,3.85,3.29,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,9V,4.44,4.8,4.11,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,3,0.63,0.71,0.57,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,19F,13.98,15.14,12.9,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,6A,11.84,13.1,10.71,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,14,15.91,17.51,14.46,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,6B,11.36,13.66,9.45,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,6A,10.87,13.05,9.06,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,3,0.77,0.83,0.72,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,7F,6.88,7.95,5.95,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,19A,21.79,25.19,18.85,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,23F,13.57,14.8,12.44,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,22F,6.22,6.74,5.74,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,1,4.59,5.26,4,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,23F,10.98,12.91,9.34,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,19F,13.35,15.47,11.52,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,9V,5.31,6.1,4.62,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,19A,19.41,20.93,18,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,6B,17.9,19.76,16.21,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,5,4.48,5.32,3.77,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,5,3.43,3.75,3.14,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03547167,Merck Sharp & Dohme LLC,Phase 3,"North America,Australia & Oceania,North America,Europe,North America,North America,Europe Asia,Australia & Oceania,North America,North America,Europe,North America,Australia & Oceania,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,South America,North America,North America,South America,North America,Australia & Oceania,North America,Europe,North America,Australia & Oceania,North America,North America,North America,Australia & Oceania,North America,Australia & Oceania,North America,Europe,North America,Europe Asia,Europe,Australia & Oceania,South America,Australia & Oceania,Europe,North America,Australia & Oceania,Europe,Europe,North America,North America,North America,North America,North America,North America,North America,North America,Australia & Oceania,North America,North America,North America,North America,North America,Europe,Australia & Oceania,North America,North America,South America,South America,Australia & Oceania,North America,North America,Australia & Oceania,North America,North America","[""Adult""]",Day 30,GMC,1,22F,0.52,0.6,0.45,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,7F,3.17,3.87,2.6,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,9V,3.24,4.01,2.62,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,19F,5.84,7.3,4.67,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,3,0.59,0.7,0.5,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,6A,3.12,4.3,2.27,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,1,2.8,3.49,2.25,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,19A,8.54,10.72,6.8,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,7F,2.45,3.15,1.91,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,4,1.26,1.57,1.1,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,9V,2.92,3.57,2.39,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,19F,5.19,6.62,4.06,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,23F,3.21,4.25,2.42,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,6B,4.69,6.25,3.52,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,22F,3.5,4.45,2.75,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,14,14.37,18.36,11.25,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,6A,3.71,5.03,2.74,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,6B,4.35,5.86,3.23,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,18C,3.96,4.95,3.18,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,5,2.61,3.28,2.08,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,18C,3.96,5.09,3.08,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,1,4.04,5,3.27,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,19A,7.23,9.02,5.8,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,3,0.51,0.61,0.43,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,5,2.13,2.68,1.69,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,14,13.68,18.1,10.34,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,4,1.61,1.98,1.31,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,22F,3.94,5.05,3.07,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,GMC,2,23F,3.74,4.91,2.85,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,23F,1266.5,1698.5,944.3,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,6B,3661.1,4900.6,2735.1,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,6A,4065.4,5415.1,3052.1,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,1,212,280.2,160.5,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,19F,2230.7,2759,1803.6,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,3,102.8,127.2,83,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,7F,5983.5,7476.1,4788.9,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,5,418.1,560.3,312.1,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,14,3634,4498.5,2935.6,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,14,2539.3,3288.9,1960.6,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,4,984.7,1255.7,772.1,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,23F,1641.2,2212.9,1217.2,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,3,96.6,117.4,79.5,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,1,154,212.4,111.6,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,6A,4593.2,5954.7,3543,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,7F,5516.5,6729.5,4522.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,9V,1929.9,2375.7,1567.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,22F,3399.9,4285,2697.6,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,18C,2511.5,3220.3,1958.7,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,18C,1753.8,2153.1,1428.6,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,9V,2454.8,3000,2008.7,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,22F,2952.7,3949.1,2207.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,4,915.4,1159.1,722.9,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,19A,3300.3,4127.7,2638.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,5,274.5,376.8,199.9,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,19F,1994.1,2438.4,1630.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,19A,3358.1,4208.4,2679.6,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Week 12,OPA,2,6B,2826.4,3626.8,2202.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6B,7.17,9.63,5.34,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6B,5.23,7.35,3.73,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,5,2.38,3.01,1.89,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19F,6.21,8.15,4.73,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19F,6.41,8.39,4.89,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,3,0.57,0.68,0.48,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,22F,0.2,0.25,0.17,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,18C,5.07,6.48,3.97,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,18C,5.58,7.18,4.33,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,1,3.16,4.01,2.48,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6A,4.91,6.91,3.49,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,23F,4.9,6.77,3.54,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,3,0.5,0.6,0.41,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,14,15.44,20.39,11.69,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,7F,2.61,3.41,2,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,1,4.27,5.5,3.31,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,7F,3.74,4.81,2.91,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,14,15.22,20.03,11.56,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,9V,3.55,4.56,2.77,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19A,9.61,12.56,7.36,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,5,2.03,2.64,1.56,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,22F,3.97,5.15,3.06,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,4,1.14,1.44,0.9,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,6A,5.13,7.04,3.73,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,23F,3.92,5.22,2.94,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,19A,9.09,11.67,7.08,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,4,2,2.55,1.56,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,GMC,1,9V,3.35,4.14,2.71,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,6A,5645.1,7447.4,4278.9,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,22F,3943.7,5100.5,3049.2,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,1,200.9,282.7,142.7,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,14,3508.7,4508.5,2730.6,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,19F,2438.6,3014.6,1972.7,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,6A,6421,8430.7,4890.4,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,18C,1560.3,2005.6,1213.8,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,5,276.7,386.7,197.9,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,5,336.7,467.7,242.4,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,23F,1757.4,2420.2,1276.1,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,19A,3715.9,4681.8,2949.2,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,18C,3002.2,3700.8,2435.5,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,19F,2042,2575.5,1618.9,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,1,238.8,329.3,173.1,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,9V,2133.9,2644.5,1721.8,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,7F,6144.3,7576.6,4982.8,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,3,116.8,143.7,94.9,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,22F,109.3,180.3,66.2,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,23F,1787,2437.9,1309,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,6B,4772.9,6278.7,3628.3,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,14,3000.3,3830.5,2350,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,4,824,1097.2,618.8,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,19A,4240.7,5265.3,3415.4,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,7F,6085.8,7602.8,4871.6,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,4,1465.5,1860.3,1154.5,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,6B,3554,4591.4,2751,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,9V,2836.3,3480.4,2311.5,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480802,Merck Sharp & Dohme LLC,Phase 3,"North America,Africa,Europe,Asia,North America,North America,North America,Asia,Africa,South America,Europe,South America,Europe","[""Adult"",""Older Adult""]",Day 30,OPA,1,3,72.3,89.2,58.6,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,7F,7.82,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,5,5.43,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,22F,5.07,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,3,0.59,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,6B,13.69,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,22F,0.31,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,18C,10.66,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,9V,5.39,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,7F,7.14,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,6A,8.22,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,23F,9.76,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,14,11.59,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,18C,16.67,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,5,5.21,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,4,2.98,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,14,12.68,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,1,6.97,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,19A,16.48,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,19F,12,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,23F,6.07,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,4,2.36,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,3,1.02,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,6B,8.35,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,19F,10.53,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,19A,18.59,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,1,7.86,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,9V,6.1,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,GMC,1,6A,11.48,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,4,1280.4,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,1,361.6,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,18C,4298.2,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,19F,2418.8,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,23F,1726.9,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,19F,2203.5,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,9V,2293,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,6B,3631.2,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,18C,2896.3,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,1,296.2,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,14,2458.1,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,3,129.4,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,4,1685.9,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,6B,5958.1,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,14,2677.3,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,6A,7352.8,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,3,245.4,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,7F,5207.6,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,23F,2648.7,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,5,655.9,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,19A,4856.1,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,19A,3783,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,7F,4966.9,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,6A,6184.2,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,5,699,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,9V,2329.9,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,22F,99.6,,,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Day 30,OPA,1,22F,3471.1,,,PCV15,1m post dose 1 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,19F,2229.7,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,6B,2872,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,18C,2379.6,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,3,262.8,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,5,583.9,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,19F,2156.2,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,23F,1485.1,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,1,392.2,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,14,2660.5,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,23F,1894.2,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,9V,1872,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,3,282.6,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,22F,1921.6,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,22F,3124.4,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,6A,2806.8,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,5,705.5,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,18C,2103.9,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,4,1580.4,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,19A,3657.1,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,9V,2059.5,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,4,1671.9,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,19A,3170.8,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,6A,3261.5,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,14,3370.9,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,7F,5125.6,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,1,283.2,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,7F,4848,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),OPA,2,6B,3223.9,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,6B,5.77,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,9V,4.96,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,19A,13.1,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,14,12.72,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,23F,4.83,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,1,5.21,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,1,5.68,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,7F,6.06,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,3,1.05,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,4,2.29,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,18C,6.29,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,6A,4.97,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,9V,4.75,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,23F,4.24,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,6B,6.71,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,5,5.77,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,22F,3.39,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,18C,7.31,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,5,5.82,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,3,1.05,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,19F,8.62,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,19A,11.88,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,6A,4.28,,,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,19F,9.38,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,22F,4.85,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,7F,5.99,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,4,1.99,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03480763,Merck Sharp & Dohme LLC,Phase 3,",North America,North America,North America,North America,North America,Asia,North America,Europe,,North America,Asia,North America,North America,North America,North America,North America,North America,North America,Europe,Europe,North America","[""Adult"",""Older Adult""]",Month 13 (30 days after Vaccination 2),GMC,2,14,14.82,,,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1 for 20vPnC followed by saline reporting group; 1 month after Vaccination 2 for 13vPnC followed by PPSV23 reporting group,OPA,1,8,1150,1401.6,944.4,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1 for 20vPnC followed by saline reporting group; 1 month after Vaccination 2 for 13vPnC followed by PPSV23 reporting group,OPA,1,1,988,1335.5,731.2,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1 for 20vPnC followed by saline reporting group; 1 month after Vaccination 2 for 13vPnC followed by PPSV23 reporting group,OPA,1,1,2604,3234.4,2096.4,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1 for 20vPnC followed by saline reporting group; 1 month after Vaccination 2 for 13vPnC followed by PPSV23 reporting group,OPA,1,8,740,915.7,598,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,14,1114,1371.4,905,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,14,1282,1614.9,1017.4,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,5,215,274.4,168.7,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,7F,1581,1836,1361.6,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,6B,2218,2865.1,1716.9,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,3,51,61.2,43.2,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,7F,1936,2269.6,1651.1,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,1,302,381.4,239.6,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,3,64,76.7,54.1,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,19A,1137,1379.4,936.5,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,6B,2006,2527.5,1591.4,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,1,454,584.5,352.6,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,9V,1164,1428,949.6,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,19A,943,1136.1,783.5,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,9V,1612,1981.4,1311.4,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,19F,738,936.5,582.1,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,18C,1322,1658.9,1053.2,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,4,1153,1504.1,883.3,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,18C,1660,2064.5,1335.1,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,23F,408,568,293,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,5,144,183.2,113.3,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,6A,2440,3219.9,1848.9,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,4,876,1134.7,676.8,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,23F,509,687.1,377.3,PCV13,1m post dose 1 adult,2 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,6A,1907,2436.2,1492.7,PCV20,1m post dose 1 adult,1 dose adult,0
NCT03313037,Pfizer,Phase 2,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after Vaccination 1,OPA,1,19F,455,592.2,349.2,PCV20,1m post dose 1 adult,1 dose adult,0
NCT02573181,Merck Sharp & Dohme LLC,Phase 2,,"[""Older Adult""]",Baseline (Day 1) and Day 30 after vaccination,GMC,2,3,3.31,4.23,2.6,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02573181,Merck Sharp & Dohme LLC,Phase 2,,"[""Older Adult""]",Baseline (Day 1) and Day 30 after vaccination,GMC,2,1,1.11,1.45,0.85,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02573181,Merck Sharp & Dohme LLC,Phase 2,,"[""Older Adult""]",Baseline (Day 1) and Day 30 after vaccination,GMC,2,1,1.27,1.64,0.98,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02573181,Merck Sharp & Dohme LLC,Phase 2,,"[""Older Adult""]",Baseline (Day 1) and Day 30 after vaccination,GMC,2,3,3.42,4.47,2.61,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02573181,Merck Sharp & Dohme LLC,Phase 2,,"[""Older Adult""]",Baseline (Day 1) and Day 30 after vaccination,OPA,2,3,91.53,127.37,65.77,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02573181,Merck Sharp & Dohme LLC,Phase 2,,"[""Older Adult""]",Baseline (Day 1) and Day 30 after vaccination,OPA,2,1,24.24,33.12,17.24,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02573181,Merck Sharp & Dohme LLC,Phase 2,,"[""Older Adult""]",Baseline (Day 1) and Day 30 after vaccination,OPA,2,1,20.3,27.7,14.87,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02573181,Merck Sharp & Dohme LLC,Phase 2,,"[""Older Adult""]",Baseline (Day 1) and Day 30 after vaccination,OPA,2,3,109.25,150.19,79.47,PCV15+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,19A,10.42,12.52,8.66,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,1,4.15,5.07,3.4,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,4,1.39,1.73,1.12,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,7F,4.69,5.84,3.78,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,6B,3.63,4.85,2.72,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,23F,3.88,4.97,3.03,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,9V,3.4,4.22,2.74,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,23F,4.27,5.57,3.27,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,9V,4.17,5.12,3.39,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,19A,14.89,18.18,12.2,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,1,5.04,6.19,4.1,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,1,4,4.79,3.34,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,3,0.48,0.58,0.39,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,6B,4.71,6.2,3.58,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,19F,3.96,4.98,3.14,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,22F,3.05,3.75,2.48,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,6A,4.4,5.88,3.29,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,14,7.31,9.22,5.79,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,23F,5.49,7.09,4.25,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,6B,3.58,4.63,2.78,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,14,10.54,13.3,8.36,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,14,6.51,8.11,5.23,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,9V,3.73,4.56,3.04,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,4,1.3,1.58,1.07,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,3,0.61,0.72,0.51,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,6A,3.88,5.06,2.98,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,3,0.94,1.12,0.78,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,4,0.96,1.16,0.79,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,19F,4.65,5.68,3.81,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,5,3.4,4.34,2.66,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,19F,7.17,9.05,5.67,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,5,3.93,5.02,3.08,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,18C,7.31,9.22,5.79,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,5,3.37,4.28,2.66,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,6A,4.56,5.96,3.49,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,18C,6.45,7.98,5.21,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,7F,4.19,5.15,3.41,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,7F,4.43,5.47,3.59,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,22F,2.75,3.36,2.25,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,22F,0.25,0.3,0.2,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,18C,6.51,8.11,5.23,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),GMC,1,19A,8.12,9.94,6.63,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,5,269.14,366.63,197.57,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,14,2664.63,3217.26,2206.92,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,4,1195.73,1534.49,931.75,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,23F,2198.15,2837.99,1702.57,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,18C,2687.1,3327.65,2169.85,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,19F,810.05,1024.61,640.41,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,18C,1896.14,2334.08,1540.37,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,23F,1561.04,2079.96,1171.58,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,6B,5082.56,6483.72,3984.2,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,1,144.01,195.54,106.06,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,19A,2477.75,3003.63,2043.94,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,5,273.79,372,201.52,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,19F,1084.99,1376.04,855.5,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,7F,2845.64,3409.92,2374.74,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,6A,4690.4,5964.93,3688.2,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,6B,4552.54,5631.79,3680.12,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,6A,4932.72,6450.62,3771.98,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,23F,1233.6,1612.25,943.88,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,4,1314.31,1644.31,1050.53,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,7F,2672.91,3227.51,2213.6,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,1,196.79,266.17,145.49,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,3,61.41,76.97,48.99,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,14,3496.71,4403.25,2776.8,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,5,283.83,383.74,209.93,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,7F,3659.86,4411.14,3036.53,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,19A,2045.57,2472.59,1692.29,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,9V,2112.91,2647.96,1685.97,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,6A,3849.02,5043.31,2937.54,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,9V,1962.09,2470.55,1558.28,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,3,104.78,131.18,83.69,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,6B,3909.05,5084.36,3005.43,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,22F,4743.78,6020.21,3737.99,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,19A,1910.75,2299.92,1587.43,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,22F,3976.66,5034.61,3141.02,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,4,929.53,1195.57,722.68,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,1,127.19,173.6,93.19,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,14,3111.5,3781.38,2560.29,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,22F,68.47,96.88,48.39,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,19F,799.86,1004.8,636.72,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,18C,1528.79,1933.45,1208.83,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,3,33.1,43.12,25.41,PCV13,1m post dose 1 adult,1 dose adult,0
NCT02547649,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",Day 30 (one month after vaccination),OPA,1,9V,2514.21,3138.57,2014.06,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,23F,0.17,0.24,0.12,PCV10 (Pneumosil),1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,6B,0.52,0.75,0.36,PCV10 (Pneumosil),1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,19F,0.13,0.17,0.09,PCV13,1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,1,0.1,0.13,0.08,PCV13,1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,23F,0.08,0.11,0.06,PCV13,1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,9V,0.1,0.13,0.07,PCV13,1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,5,0.08,0.1,0.06,PCV10 (Pneumosil),1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,19F,0.17,0.23,0.12,PCV10 (Pneumosil),1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,6B,0.14,0.19,0.1,PCV13,1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,6A,0.34,0.49,0.24,PCV13,1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,7F,0.24,0.31,0.18,PCV13,1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,14,0.41,0.62,0.27,PCV13,1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,7F,0.25,0.34,0.18,PCV10 (Pneumosil),1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,19A,0.22,0.31,0.15,PCV10 (Pneumosil),1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,5,0.17,0.23,0.13,PCV13,1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,14,0.19,0.26,0.13,PCV10 (Pneumosil),1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,9V,0.17,0.22,0.13,PCV10 (Pneumosil),1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,1,0.1,0.13,0.08,PCV10 (Pneumosil),1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,6A,0.43,0.61,0.3,PCV10 (Pneumosil),1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",20-23 weeks,GMC,4,19A,0.12,0.17,0.08,PCV13,1m post boost child,3+1 child,44
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,14,44.78,60.52,33.13,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,7F,6.07,9,4.1,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,6B,26.87,47.36,15.24,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,23F,8.95,14.28,5.61,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,7F,4.62,6.2,3.44,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,23F,10.09,16.24,6.26,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,19A,11.2,20.05,6.26,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,6A,17.09,30.29,9.64,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,6A,3.64,5.12,2.59,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,19A,19.47,31.25,12.13,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,1,12.79,19.61,8.34,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,19F,20.72,29.37,14.62,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,5,3.56,6.01,2.11,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,19F,12.38,20.37,7.53,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,9V,8.73,11.37,6.7,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,9V,4.92,7.03,3.45,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,1,3.96,6.24,2.51,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,14,48.23,73.62,31.6,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,5,4.8,7.51,3.07,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,1,6B,12.12,18.07,8.12,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks (28 days),GMC,4,1,0.27,0.33,0.22,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks (28 days),GMC,4,1,0.32,0.4,0.27,PCV13,1m post boost child,3+1 child,40
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks (28 days),GMC,4,4,3.23,3.78,2.76,PCV13,1m post boost child,3+1 child,40
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks (28 days),GMC,4,4,2.67,3.21,2.22,PCV10 (Pneumosil),1m post boost child,3+1 child,40
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,6A,1.82,2.17,1.53,PCV13,1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,5,1.74,1.98,1.53,PCV13,1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,9V,1.07,1.23,0.93,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,14,4.96,5.87,4.2,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,1,2.99,3.43,2.61,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,19F,3.87,4.49,3.35,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,14,4.47,5.53,3.62,PCV13,1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,6B,3.64,4.42,3.01,PCV13,1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,19F,5.38,6.05,4.79,PCV13,1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,6A,1.02,1.27,0.83,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,9V,2.19,2.5,1.91,PCV13,1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,7F,2.19,2.53,1.89,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,1,3.38,3.78,3.02,PCV13,1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,23F,1.56,1.83,1.32,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,7F,3.88,4.38,3.44,PCV13,1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,6B,1.57,1.92,1.28,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,19A,1.49,1.76,1.26,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,23F,2.68,3.15,2.28,PCV13,1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,5,2.09,2.36,1.86,PCV10 (Pneumosil),1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after the third dose,GMC,3,19A,5.2,6.2,4.37,PCV13,1m post primary child,3+1 child,18
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,6A,19371.45,34268.51,12538.18,PCV10 (Pneumosil),1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,5,113.92,167.1,74.12,PCV10 (Pneumosil),1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,5,265.56,521.05,143.22,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,14,6707.26,7886.64,5098.03,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,5,1358.22,2087.48,960.34,PCV10 (Pneumosil),1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,14,1243.39,1912.05,743.97,PCV10 (Pneumosil),1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,19A,3170.33,4427.88,1906.55,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,7F,8019.15,10917.82,4956.82,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,19F,3036.6,5126.44,2134.81,PCV10 (Pneumosil),1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,23F,10517.81,19460.6,5848.87,PCV13,1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,19A,3780.56,6045.56,2358.04,PCV13,1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,19F,3564.32,4898.79,2636.19,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,1,29.42,68.08,15.58,PCV13,1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,5,1148.43,1708.67,929.92,PCV13,1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,9V,4443.95,6299.32,3275.91,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,9V,3928.12,5629.89,2827.41,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,19F,498.98,723.41,275.77,PCV13,1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,1,438.14,890.17,278.73,PCV13,1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,7F,3763.17,5393.72,2754.89,PCV13,1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,1,18.89,45.59,10.14,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,7F,876.58,1221.31,616.9,PCV10 (Pneumosil),1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,19F,3371.52,5853.53,2238.81,PCV13,1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,19F,744.92,941.74,607.87,PCV10 (Pneumosil),1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,1,436.31,582.46,365.08,PCV10 (Pneumosil),1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,6B,1530.37,2368.41,935.24,PCV10 (Pneumosil),1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,5,263.06,499.28,138.91,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,14,8213.23,13664.12,4526.63,PCV10 (Pneumosil),1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,6A,3068.16,5318.41,2267.85,PCV13,1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,19F,2481.47,3860.16,1623.91,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,19A,1789.98,3498.32,651.04,PCV10 (Pneumosil),1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,19A,2215.22,3458.76,1314.65,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,23F,5035.73,7587.87,3417.87,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,14,9148.12,12407.65,6271.81,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,19A,765.71,886.28,589.49,PCV13,1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,7F,10723.98,16590.09,7151.48,PCV10 (Pneumosil),1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,6B,7066.76,11894.25,4456.49,PCV13,1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,6B,8768.08,12932.67,5471.57,PCV10 (Pneumosil),1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,9V,4862.3,6953.05,3128.56,PCV13,1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,23F,921.43,1419.94,574.79,PCV13,1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,23F,2844.04,3737.09,2123.33,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,14,2557.27,3868.34,1597.17,PCV13,1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,6A,17161.52,23946.2,12378.36,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,6B,13303.68,18190.05,9432.51,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,7F,12737.21,18328.98,8063.57,PCV13,1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,9V,3770.19,6384.49,2004.45,PCV10 (Pneumosil),1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,6A,12001.09,21545.31,8229.26,PCV13,1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,6B,2267.44,3718.87,1175.92,PCV13,1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,6B,4221.68,5925.09,2890.62,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,19A,151.31,233.45,64.25,PCV10 (Pneumosil),1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,9V,197.24,347.56,95.09,PCV10 (Pneumosil),1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,7F,7099.73,11222.44,4147.2,PCV10 (Pneumosil),1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,14,1108.02,2097.51,501.79,PCV13,1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,1,50.65,96.55,27.91,PCV10 (Pneumosil),1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,6A,1243.88,1834.3,942.4,PCV10 (Pneumosil),1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,9V,752.77,1024.26,528.18,PCV13,1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,6A,4925.68,7661.38,3204.91,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,5,104.83,181.22,64.11,PCV13,1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,1,1,85.89,215.84,43.15,PPV23,1m post dose 1 adult,1 dose adult,0
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,3,23F,627.27,975.77,341.95,PCV10 (Pneumosil),1m post primary child,3+1 child,14
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after last vaccination,OPA,4,23F,12415.92,19342.91,8018.97,PCV10 (Pneumosil),1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,4,1,0.92,1.26,0.72,PCV13,1m post boost child,3+1 child,52
NCT02308540,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",4 weeks after vaccination,GMC,4,1,0.77,1.36,0.46,PCV10 (Pneumosil),1m post boost child,3+1 child,52
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,14,5.01,6.38,3.94,PCV13,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,23F,1.13,1.47,0.87,PCV13,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,1,1.48,1.83,1.2,PCV13,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,3,0.43,0.54,0.35,PCV13,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,5,1.63,2.14,1.25,PCV13,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,19F,1.89,2.3,1.56,PCV13,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,7F,2.9,3.39,2.48,PCV13,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,18C,1.41,1.74,1.14,PCV13,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,6A,2.75,3.31,2.28,PCV13,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,22F,0.06,0.08,0.05,PCV13,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,19A,1.45,1.86,1.13,PCV13,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,4,0.98,1.22,0.78,PCV13,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,9V,1.35,1.74,1.05,PCV13,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,6B,2.24,3.24,1.54,PCV13,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,6A,6.93,10.22,4.69,PCV15,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,9V,3.25,4.29,2.47,PCV13,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,19A,5.11,6.23,4.19,PCV13,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,23F,3.91,5.05,3.03,PCV13,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,9V,2.96,4.36,2.01,PCV15,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,1,2.33,2.95,1.84,PCV13,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,22F,7.21,10.4,4.99,PCV15,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,23F,2.01,2.83,1.43,PCV15,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,22F,0.08,0.12,0.06,PCV13,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,4,1.78,2.39,1.33,PCV13,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,7F,5.65,6.88,4.65,PCV13,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,5,4.72,5.86,3.8,PCV13,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,4,1.71,2.41,1.21,PCV15,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,19F,6.07,8.37,4.4,PCV15,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,14,7.48,9.67,5.79,PCV13,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,5,2.31,3.22,1.66,PCV15,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,7F,4.69,6.4,3.44,PCV15,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,3,0.62,0.77,0.49,PCV13,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,19A,3.65,4.95,2.69,PCV15,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,6A,10.31,12.92,8.22,PCV13,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,18C,2.84,3.47,2.31,PCV13,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,3,1.1,1.51,0.81,PCV15,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,6B,11.55,14.35,9.3,PCV13,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,18C,2.06,2.77,1.54,PCV15,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,6B,7.35,10.88,4.96,PCV15,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,14,8.68,12.8,5.89,PCV15,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,19F,5.11,6.23,4.19,PCV13,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",One month following the 4th vaccination (approximately 13 to 16 months of age),GMC,4,1,1.67,2.41,1.16,PCV15,1m post boost child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,23F,1.02,1.4,0.75,PCV15,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,7F,2.09,2.64,1.65,PCV15,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,22F,4.1,5.53,3.04,PCV15,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,9V,1,1.33,0.75,PCV15,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,5,1.16,1.53,0.88,PCV15,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,19F,2.31,3.04,1.75,PCV15,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,6A,1.64,2.61,1.04,PCV15,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,6B,0.77,1.32,0.45,PCV15,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,14,2.96,4.48,1.95,PCV15,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,19A,1.27,1.62,0.99,PCV15,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,3,0.96,1.22,0.75,PCV15,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,18C,1.29,1.6,1.05,PCV15,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,1,1.2,1.48,0.98,PCV15,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 7 (1 month PD3),GMC,3,4,1.33,1.66,1.07,PCV15,1m post primary child,3+1 child,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 2 (1 month after a single vaccination),GMC,1,6B,8.96,19.34,4.15,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 2 (1 month after a single vaccination),GMC,1,19A,9.71,18.94,4.98,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 2 (1 month after a single vaccination),GMC,1,5,2.63,6.84,1.01,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 2 (1 month after a single vaccination),GMC,1,18C,4.56,8.98,2.32,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 2 (1 month after a single vaccination),GMC,1,14,16.24,35.54,7.42,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 2 (1 month after a single vaccination),GMC,1,19F,3.39,7.15,1.61,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 2 (1 month after a single vaccination),GMC,1,1,3.19,5.97,1.71,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 2 (1 month after a single vaccination),GMC,1,22F,6.05,13.75,2.66,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 2 (1 month after a single vaccination),GMC,1,6A,8.23,15.86,4.26,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 2 (1 month after a single vaccination),GMC,1,23F,4.78,11.26,2.03,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 2 (1 month after a single vaccination),GMC,1,7F,4.88,10.75,2.22,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 2 (1 month after a single vaccination),GMC,1,4,2.28,4.18,1.25,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 2 (1 month after a single vaccination),GMC,1,3,0.84,1.47,0.47,PCV15,1m post dose 1 adult,1 dose adult,0
NCT02037984,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",Month 2 (1 month after a single vaccination),GMC,1,9V,4.96,10.56,2.33,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01646398,Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Older Adult""]",One month after vaccination,OPA,1,4,1016,1213.2,850.7,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01646398,Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Older Adult""]",One month after vaccination,OPA,1,5,44,51.5,38.1,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01646398,Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Older Adult""]",One month after vaccination,OPA,1,3,103,125.5,84.6,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01646398,Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Older Adult""]",One month after vaccination,OPA,1,5,44,51.5,38.1,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01646398,Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Older Adult""]",One month after vaccination,OPA,1,3,103,125.5,84.6,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01646398,Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Older Adult""]",One month after vaccination,OPA,1,4,1016,1213.2,850.7,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01641133,GlaxoSmithKline,Phase 3,"North America,North America,North America","[""Child""]","At study Month 3 (one month after the primary vaccination), at study Month 10 (prior to booster vaccination) and at study Month 11 (one month after the booster vaccination)",OPA,2,1,10.3,13.2,8.1,PCV10 (Synflorix),1m post primary child,2+1 child,0
NCT01641133,GlaxoSmithKline,Phase 3,"North America,North America,North America","[""Child""]","At study Month 3 (one month after the primary vaccination), at study Month 10 (prior to booster vaccination) and at study Month 11 (one month after the booster vaccination)",OPA,2,3,58.9,87.9,39.4,PCV10 (Synflorix),1m post primary child,2+1 child,0
NCT01641133,GlaxoSmithKline,Phase 3,"North America,North America,North America","[""Child""]","At study Month 3 (one month after the primary vaccination), at study Month 10 (prior to booster vaccination) and at study Month 11 (one month after the booster vaccination)",GMC,2,3,2.74,3.24,2.32,PCV10 (Synflorix),1m post primary child,2+1 child,0
NCT01641133,GlaxoSmithKline,Phase 3,"North America,North America,North America","[""Child""]","At study Month 3 (one month after the primary vaccination), at study Month 10 (prior to booster vaccination) and at study Month 11 (one month after the booster vaccination)",GMC,2,1,0.34,0.4,0.29,PCV10 (Synflorix),1m post primary child,2+1 child,0
NCT01545375,GlaxoSmithKline,Phase 2,"North America,North America,North America,North America,North America","[""Child""]","One month post-dose 3 [PIII(Month 5)], prior to booster dose [PIII(Month 10)] and one month post-booster dose [Post-booster(Month 11)]",GMC,4,5,3.18,3.62,2.8,PCV13,1m post boost child,3+1 child,0
NCT01545375,GlaxoSmithKline,Phase 2,"North America,North America,North America,North America,North America","[""Child""]","One month post-dose 3 [PIII(Month 5)], prior to booster dose [PIII(Month 10)] and one month post-booster dose [Post-booster(Month 11)]",GMC,4,1,0.55,0.62,0.49,PCV13,1m post boost child,3+1 child,0
NCT01545375,GlaxoSmithKline,Phase 2,"North America,North America,North America,North America,North America","[""Child""]",One month post-dose 3 [PIII(Month 5)] and one month post-booster dose [Post-booster(Month 11)],OPA,4,6C,2616.6,3558.2,1924.2,PCV13,1m post boost child,3+1 child,0
NCT01545375,GlaxoSmithKline,Phase 2,"North America,North America,North America,North America,North America","[""Child""]",One month post-dose 3 [PIII(Month 5)] and one month post-booster dose [Post-booster(Month 11)],OPA,4,5,32.9,53.7,20.2,PCV13,1m post boost child,3+1 child,0
NCT01545375,GlaxoSmithKline,Phase 2,"North America,North America,North America,North America,North America","[""Child""]",One month post-dose 3 [PIII(Month 5)] and one month post-booster dose [Post-booster(Month 11)],OPA,4,1,219.7,358.5,134.7,PCV13,1m post boost child,3+1 child,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,19A,9.36,11.44,7.66,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,23F,3.41,4.43,2.62,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,19F,4.8,6.04,3.81,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,5,3.99,4.92,3.23,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,6B,5.43,7.17,4.11,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,19A,11.36,13.92,9.28,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,3,0.56,0.66,0.47,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,9V,4.05,4.93,3.32,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,4,2.09,2.56,1.7,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,6A,4.88,6.39,3.73,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,6B,2.81,3.62,2.19,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,22F,5.21,6.39,4.25,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,4,1.96,2.41,1.59,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,7F,6.06,7.48,4.91,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,22F,0.38,0.44,0.32,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,6A,4.86,6.13,3.86,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,5,2.76,3.44,2.21,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,1,3.12,3.82,2.54,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,7F,4.59,5.66,3.72,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,9V,3.41,4.2,2.77,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,23F,5.55,7.12,4.33,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,14,8.9,11.18,7.08,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,3,1.13,1.35,0.96,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,1,3.76,4.65,3.05,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,18C,8,9.68,6.62,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,14,8.56,10.69,6.86,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,19F,3.35,4.21,2.67,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,GMC,1,18C,6.83,8.2,5.68,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,23F,2217.18,3093.71,1588.99,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,18C,3358.41,4231.06,2665.75,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,1,208.03,276.78,156.36,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,6B,6469.99,8766.16,4775.27,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,14,4478.38,5499.22,3647.04,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,23F,1197.8,1714.53,836.8,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,1,115.75,156.31,85.72,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,9V,2471.1,3243.6,1882.58,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,22F,57.45,88.5,37.29,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,5,372.35,510.19,271.76,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,19F,1946.04,2447.35,1547.41,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,4,3001.63,3784.72,2380.57,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,22F,8329.52,10604.06,6542.87,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,7F,5148.66,6356.06,4170.62,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,3,595.16,710.95,498.23,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,6B,4207.86,5511.7,3212.46,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,14,4352.27,5613.15,3374.62,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,7F,7816.74,9608.81,6358.89,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,9V,3024.34,3910.96,2338.72,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,18C,4631.86,5750.96,3730.53,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,6A,4216.34,5971.49,2977.07,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,19F,1201.17,1592.15,906.2,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,4,2875.79,3732.69,2215.61,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,6A,5251.47,6702,4114.87,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,19A,3391.18,4174,2755.18,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,5,712.21,943.22,537.78,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,3,256.76,310.85,212.08,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01513551,Merck Sharp & Dohme LLC,Phase 2,,"[""Adult"",""Older Adult""]",One month postvaccination,OPA,1,19A,4186.28,5122.46,3421.2,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,7F,5818.1,6844.8,4945.3,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,19F,986.2,1362.2,714,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,19A,551.7,794.1,383.3,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,22F,3.9,5.5,2.8,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,6A,4009.7,4848.4,3316,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,22F,3048.8,3741.5,2484.3,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,18C,1263.7,1542.2,1035.4,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,3,209.9,246.7,178.6,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,7F,10454.1,12687,8614.1,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,1,44.6,63.7,31.2,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,9V,2227.4,2770.1,1791,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,23F,3040.3,4110.1,2249,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,14,2786.5,3459.7,2244.3,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,6A,1273.6,2009.1,807.3,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,19F,1417.1,1753.3,1145.4,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,6B,1597.5,2227.4,1145.7,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,6B,765.5,1265.2,463.2,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,23F,1087.7,1439.8,821.8,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,14,2266.2,2797.2,1835.9,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,4,1911.6,2272.4,1608,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,5,467.6,591.7,369.4,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,19A,1292.1,1810.9,921.9,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,4,1672.9,1978.7,1414.3,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,9V,2685.5,3417.1,2110.5,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,18C,2209,2662,1833.1,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,3,296.7,356.6,246.9,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,5,542.8,706.7,416.8,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,OPA,3,1,35.4,49.3,25.4,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,1,1.84,2.01,1.69,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,4,1.28,1.39,1.18,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,5,1.83,2.02,1.65,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,9V,1.79,1.97,1.63,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,4,1.32,1.43,1.22,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,23F,1.41,1.58,1.25,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,18C,1.99,2.19,1.81,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,3,0.5,0.55,0.46,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,22F,5.24,5.79,4.74,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,19A,0.9,1,0.8,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,19F,1.5,1.69,1.33,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,1,1.34,1.45,1.24,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,19A,2.05,2.27,1.85,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,23F,1.05,1.17,0.94,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,22F,0.07,0.07,0.06,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,9V,1.49,1.64,1.35,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,3,0.95,1.03,0.88,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,14,5.62,6.28,5.02,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,6A,2.91,3.24,2.62,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,6B,1.47,1.69,1.27,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,19F,2.54,2.75,2.35,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,7F,2.63,2.87,2.41,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,7F,3.67,3.97,3.4,PCV13,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,6A,0.93,1.08,0.8,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,14,4.17,4.63,3.76,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,5,1.61,1.77,1.46,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,6B,0.95,1.15,0.78,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 3,GMC,3,18C,1.27,1.39,1.17,PCV15,1m post primary child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,6A,2583.6,4004.2,1667,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,18C,3214.7,4238.9,2438,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,14,3872.9,5430.5,2762.1,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,19F,1885.8,2899.2,1226.6,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,7F,19147.5,26710.7,13725.9,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,1,139.1,215,90,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,5,830.3,1144.8,602.1,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,22F,4586.5,6175.7,3406.2,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,6A,7382,10007.6,5445.2,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,3,438.6,557.9,344.8,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,18C,1327,1862.8,945.3,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,19A,1871,2730.4,1282.1,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,4,1674.3,2392.9,1171.5,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,9V,2888,4201.7,1985,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,14,3543.1,5005,2508.3,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,4,2456.5,3184.2,1895.1,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,7F,10205.9,13911.2,7487.6,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,3,369.7,465,293.8,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,22F,4.8,8.8,2.6,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,23F,11490,16892.4,7815.4,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,1,133.1,205.1,86.3,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,9V,4901.5,6423.2,3740.3,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,6B,4686.1,7179.3,3058.7,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,23F,3118,4412.6,2203.2,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,6B,3866.8,5489.7,2723.7,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,5,680.8,976.6,474.7,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,19F,2624.6,3691.5,1866,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,OPA,4,19A,4519.7,6744.7,3028.7,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,9V,2.82,3.15,2.52,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,6B,5.24,5.86,4.68,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,23F,3.14,3.54,2.78,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,22F,9.64,10.62,8.74,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,18C,3.37,3.71,3.06,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,19F,4.51,5,4.07,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,3,0.69,0.75,0.63,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,14,6.05,6.82,5.37,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,1,2.18,2.38,1.99,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,4,1.46,1.65,1.3,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,6A,3.78,4.26,3.37,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,7F,5.73,6.28,5.24,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,5,2.53,2.81,2.28,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,23F,1.99,2.26,1.75,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,7F,4.18,4.64,3.76,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,6B,5.51,6.2,4.9,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,19A,3.04,3.4,2.72,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,14,7.57,8.42,6.81,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,1,1.91,2.1,1.73,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,6A,6.55,7.28,5.89,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,4,1.68,1.86,1.52,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,22F,0.12,0.14,0.11,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,3,1.26,1.39,1.15,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,18C,2.14,2.37,1.94,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,19F,5.56,6.2,4.99,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,5,1.93,2.14,1.74,PCV15,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,19A,6.14,6.78,5.57,PCV13,1m post boost child,3+1 child,0
NCT01215188,Merck Sharp & Dohme LLC,Phase 2,,"[""Child""]",One month postvaccination 4,GMC,4,9V,3.37,3.72,3.04,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,23F,8664.4,23949.3,3134.6,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,18C,6287.9,14473.4,2731.8,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,4,8928.4,12780.7,6237.2,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,6A,3475.2,12939.6,933.3,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,9V,18343.5,28295.5,11891.7,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,3,357.9,637.8,200.8,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,6C,10940.7,20179.8,5931.6,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,5,8.1,19.9,3.3,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,7F,11685.4,27637,4940.8,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,18C,12180.6,18866.5,7864,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,14,13145.2,21449.6,8055.9,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,23F,8616,16947.8,4380.2,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,19A,2778,4700.1,1642,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,1,3.7,6.9,2,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,3,26.1,60.4,11.3,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,22F,11404.1,35251.2,3689.3,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,1,471.9,1055.2,211,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,9V,29321.9,51798.8,16598.3,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,6C,462.6,2159.4,99.1,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,19F,4597.9,6502.8,3251.1,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,19F,2665.8,5714.9,1243.5,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,22F,41.2,180.6,9.4,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,19A,8458.3,11414.2,6267.9,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,7F,261.4,1232.4,55.4,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,6B,21795.1,36911.7,12869.3,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,14,17469.5,29029.7,10512.8,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,6A,21117.8,33055.2,13491.5,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,6B,9073.3,23685.6,3475.8,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,5,2405.5,6562,881.8,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,1,4,9684.2,13115.2,7150.8,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,1,94,157.4,56.1,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,6C,534.8,1734.3,164.9,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,9V,7435.1,12103.1,4567.4,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,3,438.8,603.6,319,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,6A,2894,5818.1,1439.5,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,19A,378.7,1000.3,143.3,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,23F,7058.5,11218.5,4441.1,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,4,2933.4,4435.5,1939.9,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,5,2,2,2,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,18C,2119,3258.5,1378,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,19F,2493.4,3966.2,1567.5,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,6C,171.7,959,30.7,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,7F,56,258.9,12.1,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,7F,12555.7,19120.9,8244.6,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,9V,5154.5,7264.9,3657.2,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,1,2,2,2,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,5,477.6,884.8,257.8,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,22F,6736.5,9876.8,4594.7,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,22F,4.1,12,1.4,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,19F,1136.4,1757.5,734.7,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,4,5163.6,7203.9,3701.1,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,6B,6884.6,11304.3,4192.9,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,6B,8309.3,13767.3,5015.1,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,14,7954.7,14399.9,4394.2,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,23F,18352.1,32186.3,10464,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,19A,1275.2,2263.9,718.3,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,18C,3862,5918.3,2520.1,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,6A,2435.8,6047.2,981.1,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,3,33.8,71,16.1,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,OPA,4,14,5868.1,10177.7,3383.3,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,6A,2.2,4.6,1.1,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,22F,12.5,17.8,8.7,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,19A,1.6,2.4,1.1,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,5,1.8,2.5,1.3,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,6B,7,10.9,4.5,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,6A,3.5,6,2.1,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,9V,5.9,9.9,3.6,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,18C,3.9,5.8,2.7,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,19F,4.2,6.1,2.8,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,3,0.4,0.5,0.3,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,14,10.8,18.8,6.1,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,9V,3.3,4.6,2.4,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,23F,4.3,6,3.1,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,7F,2,3,1.4,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,4,1.5,2.2,1,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,1,0.1,0.1,0,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,4,2.8,4,1.9,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,1,3,4.1,2.3,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,18C,2.1,3.1,1.4,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,22F,0.2,0.3,0.1,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,5,0.7,1,0.4,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,6B,7.1,10.6,4.8,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,19F,1.9,2.7,1.4,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,19A,1.7,2.7,1,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,23F,7.1,10.9,4.6,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,14,9.4,14.7,6,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,3,2.2,3,1.6,PCV13+PCV15,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,4,7F,0.1,0.2,0.1,PCV13,1m post boost child,3+1 child,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,9V,7.4,12.4,4.4,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,19F,7.5,12.7,4.5,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,3,1.1,1.5,0.8,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,6B,5.9,13.8,2.5,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,1,0.7,1,0.5,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,23F,14.2,25.9,7.8,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,5,15.1,27.5,8.3,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,6A,4,8.6,1.9,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,6A,12.4,24.6,6.3,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,18C,14.7,24.8,8.7,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,19A,19.1,28.8,12.7,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,18C,8.6,16.7,4.5,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,3,2.9,4.3,2,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,14,25.8,42,15.8,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,23F,11.2,21.7,5.8,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,9V,7.9,13.2,4.8,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,22F,0.7,1,0.5,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,4,4.2,6.9,2.6,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,7F,6.8,12,3.9,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,7F,0.7,1,0.5,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,1,7.9,13.8,4.5,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,19F,12.1,20.6,7.1,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,19A,5.8,9.5,3.5,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,14,12.5,23.4,6.7,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,5,1.8,2.4,1.4,PCV13,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,6B,20.1,37.2,10.9,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,22F,5.9,8.9,3.8,PCV15,1m post dose 1 adult,1 dose adult,0
NCT01215175,Merck Sharp & Dohme LLC,Phase 1,,"[""Child"",""Adult""]",Day 30 after vaccination,GMC,1,4,3.4,5,2.3,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,19A,8.82,10.43,7.45,PCV13,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,23F,5.51,6.81,4.46,PCV13,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,18C,4.87,5.9,4.01,PCV7,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,1,7.62,9.21,6.3,PCV13,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,14,12.04,14.63,9.9,PCV7,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,6A,11.55,13.81,9.66,PCV13,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,5,0.95,1.13,0.8,PCV7,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,19F,8.07,9.9,6.58,PCV13,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,3,1.29,1.53,1.09,PCV13,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,9V,3.18,3.8,2.66,PCV13,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,5,4.57,5.39,3.87,PCV13,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,19A,1.98,2.32,1.69,PCV7,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,23F,7.97,9.68,6.55,PCV7,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,6B,13.62,16.73,11.08,PCV13,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,3,0.12,0.16,0.09,PCV7,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,7F,0.06,0.07,0.04,PCV7,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,6A,3.79,4.76,3.01,PCV7,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,1,0.03,0.03,0.02,PCV7,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,14,8.17,10.22,6.53,PCV13,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,9V,3.88,4.6,3.27,PCV7,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,19F,7.41,8.92,6.16,PCV7,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,6B,13.28,16.21,10.87,PCV7,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,4,4.06,4.93,3.34,PCV13,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,7F,5.91,7.06,4.95,PCV13,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,4,6.34,7.65,5.26,PCV7,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the toddler dose (16 months of age),GMC,4,18C,3.67,4.49,3,PCV13,1m post boost child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,6B,4.37,5.33,3.58,PCV13,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,14,11.59,13.71,9.79,PCV7,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,4,4.64,5.37,4,PCV7,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,3,0.05,0.06,0.04,PCV7,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,23F,1.93,2.37,1.56,PCV13,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,19F,4.77,5.47,4.17,PCV7,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,6A,4.57,5.34,3.92,PCV13,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,5,0.43,0.53,0.35,PCV7,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,19A,3.69,4.24,3.2,PCV13,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,4,2.89,3.42,2.45,PCV13,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,6B,4.82,5.67,4.09,PCV7,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,18C,2.39,2.82,2.04,PCV13,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,6A,0.79,0.99,0.63,PCV7,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,7F,3.67,4.29,3.14,PCV13,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,7F,0.04,0.05,0.03,PCV7,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,9V,1.97,2.27,1.7,PCV13,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,9V,2.92,3.34,2.55,PCV7,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,19F,3.6,4.32,3,PCV13,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,19A,2.46,2.84,2.13,PCV7,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,1,0.02,0.02,0.02,PCV7,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,14,9.76,11.43,8.34,PCV13,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,18C,3.07,3.56,2.64,PCV7,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,3,1.2,1.45,1,PCV13,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,1,4.14,4.96,3.45,PCV13,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,23F,3.25,3.8,2.78,PCV7,1m post primary child,3+1 child,0
NCT00688870,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,5,2.47,2.92,2.09,PCV13,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,3,0.04,0.05,0.03,PCV7,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,19A,2.65,3.06,2.29,PCV7,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,5,5.06,5.85,4.37,PCV13,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,4,5.4,6.3,4.62,PCV13,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,23F,4.29,5.16,3.56,PCV13,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,1,0.02,0.03,0.02,PCV7,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,4,6.97,8.18,5.94,PCV7,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,19F,3.88,4.72,3.18,PCV13,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,6A,0.64,0.82,0.49,PCV7,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,18C,4.57,5.24,3.98,PCV13,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,7F,0.04,0.05,0.03,PCV7,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,3,1.6,1.89,1.35,PCV13,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,9V,3.33,3.83,2.9,PCV13,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,6B,4.88,6.01,3.96,PCV7,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,6B,5.71,7.03,4.64,PCV13,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,5,0.39,0.49,0.3,PCV7,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,14,16.29,19.85,13.36,PCV7,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,9V,3.78,4.33,3.31,PCV7,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,6A,5.73,7.07,4.64,PCV13,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,23F,4.11,4.98,3.4,PCV7,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,19A,5.94,6.89,5.13,PCV13,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,19F,4.2,4.96,3.55,PCV7,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,7F,6.97,8,6.07,PCV13,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,1,7.44,8.85,6.25,PCV13,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,18C,4.73,5.47,4.09,PCV7,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the infant series (7 months of age),GMC,3,14,14.83,17.77,12.38,PCV13,1m post primary child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,6B,15.14,19.25,11.91,PCV7,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,1,9.29,11.28,7.65,PCV13,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,14,15.64,18.72,13.07,PCV7,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,6A,3.33,4.14,2.67,PCV7,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,7F,0.1,0.14,0.07,PCV7,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,1,0.04,0.05,0.03,PCV7,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,4,8.25,9.89,6.88,PCV7,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,9V,4.83,5.67,4.12,PCV7,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,7F,11.17,13.37,9.33,PCV13,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,4,6.46,7.9,5.29,PCV13,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,19F,7.75,9.53,6.3,PCV13,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,23F,10.95,13.66,8.77,PCV13,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,5,1.31,1.56,1.09,PCV7,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,3,1.65,1.95,1.4,PCV13,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,14,11.51,13.8,9.59,PCV13,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,5,8.92,10.45,7.62,PCV13,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,6B,16.81,19.68,14.36,PCV13,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,18C,6.86,8.29,5.67,PCV13,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,19A,10.12,11.98,8.55,PCV13,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,3,0.1,0.13,0.08,PCV7,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,19F,5.35,6.33,4.52,PCV7,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,6A,13.58,16.36,11.28,PCV13,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,9V,4.59,5.38,3.91,PCV13,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,23F,10.44,12.68,8.6,PCV7,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,18C,7.44,8.83,6.27,PCV7,1m post boost child,3+1 child,0
NCT00689351,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 2,",,,,,","[""Child""]",1 month after the Toddler Dose (13 months of age),GMC,4,19A,2.38,2.78,2.04,PCV7,1m post boost child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,19A,0.12,0.14,0.1,PCV13,1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,19A,0.29,0.33,0.25,PCV10 (Synflorix),1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,6A,0.38,0.44,0.33,PCV10 (Synflorix),1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,6A,0.48,0.63,0.36,PCV13,1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,9V,3.39,3.71,3.09,PCV10 (Synflorix),1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,4,5.35,6.15,4.66,PCV13,1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,5,0.07,0.08,0.06,PCV13,1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,18C,5.13,6.11,4.31,PCV13,1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,14,8.51,9.95,7.27,PCV13,1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,19F,7.41,8.23,6.67,PCV10 (Synflorix),1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,23F,1.96,2.19,1.75,PCV10 (Synflorix),1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,1,3.41,3.71,3.14,PCV10 (Synflorix),1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,9V,5.09,5.96,4.34,PCV13,1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,14,5.54,6.12,5.02,PCV10 (Synflorix),1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,7F,4.08,4.41,3.77,PCV10 (Synflorix),1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,4,4,4.35,3.67,PCV10 (Synflorix),1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,5,4.52,4.83,4.24,PCV10 (Synflorix),1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,19F,2.77,3.13,2.45,PCV13,1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,6B,1.4,1.58,1.24,PCV10 (Synflorix),1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,18C,5.8,6.52,5.17,PCV10 (Synflorix),1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,23F,3.94,4.77,3.26,PCV13,1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,6B,2.07,2.44,1.75,PCV13,1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,1,0.04,0.05,0.04,PCV13,1m post primary child,3+1 child,0
NCT00680914,GlaxoSmithKline,Phase 3,",,,,,,,,,,,,,","[""Child""]",One month after the administration of the 3rd vaccine dose of the pneumococcal conjugate vaccine,GMC,3,7F,0.03,0.04,0.03,PCV13,1m post primary child,3+1 child,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,19F,696,887.7,546.3,PCV13,1m post dose 1 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,9V,406,564.6,292.3,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,18C,1074,1322.2,871.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,19A,696,833.6,581.1,PCV13,1m post dose 1 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,14,616,802.2,473.3,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,19A,457,536.3,389.5,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,1,140,168.1,117.4,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,23F,358,481.7,265.5,PCV13,1m post dose 1 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,7F,1252,1614.4,971.1,PCV13,1m post dose 1 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,6B,2012,2574.1,1571.9,PCV13,1m post dose 1 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,1,220,269.3,178.9,PCV13,1m post dose 1 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,4,1430,1683.9,1214.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,6B,1351,1677,1087.6,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,9V,758,1018.9,563.8,PCV13,1m post dose 1 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,3,74,88.7,61.3,PCV13,1m post dose 1 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,4,2517,3029.2,2091.7,PCV13,1m post dose 1 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,5,188,234.8,151.1,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,19F,773,937.6,636.6,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,18C,1532,1982.7,1183.7,PCV13,1m post dose 1 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,3,129,147.5,112.4,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,14,664,908.5,485.1,PCV13,1m post dose 1 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,7F,533,678.2,419.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,5,227,300.5,170.9,PCV13,1m post dose 1 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,23F,216,282.7,165,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,9V,114,169.3,76.5,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,7F,537,682.6,422.4,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,5,199,246.2,161.4,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,19A,467,541,403.5,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,5,85,112,64.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,19F,286,376.7,217.3,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,14,622,796.4,485.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,18C,1062,1307.6,863.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,23F,198,259.4,151.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,4,1385,1638.7,1171.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,6B,710,953.2,529.1,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,4,935,1182.4,739.9,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,23F,124,173,88.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,7F,126,184.6,85.6,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,9V,373,517.6,268.4,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,1,77,98.1,60.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,6B,1215,1528.3,965.4,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,3,50,61.7,40.9,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,3,125,143.4,108.6,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,19F,774,933.6,642,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,19A,289,353.9,235.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,1,148,176.5,123.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,14,435,585.7,323,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,18C,564,761.7,418.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,4,935,1182.4,739.9,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,5,85,112,64.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,1,207,240.9,177.7,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,9V,767,949.3,620,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,19F,711,848.9,595.9,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,5,215,261.7,175.9,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,18C,1576,1880.9,1321.3,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,23F,124,173,88.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,14,650,805.8,524.9,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,19A,709,811.2,618.9,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,7F,1063,1302.2,868.6,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,23F,354,440.7,283.8,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,14,435,585.7,323,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,6B,710,953.2,529.1,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,3,50,61.7,40.9,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,9V,114,169.3,76.5,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,6B,1948,2351.7,1614,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,19A,289,353.9,235.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,19F,286,376.7,217.3,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,18C,564,761.7,418.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,3,75,85.3,66,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,1,77,98.1,60.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,2,7F,126,184.6,85.6,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT00574548,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America","[""Adult""]",1 month after vaccination 1 (Vax 1=Day 1/ Year 0 [Visit 1]) and 1 month after vaccination 2 (Vax 2=Day 351 up to Day 379 after Visit 1),OPA,1,4,2536,2933,2192.3,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,19A,354,408.4,307.7,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,19A,200,234.4,170,PPV23,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,6B,417,526.7,330.5,PPV23,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,23F,43,53.5,34.2,PPV23,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,9V,90,119.7,67.8,PPV23,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,23F,158,198.6,126,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,4,203,262.2,157.1,PPV23,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,7F,160,207.9,123.5,PPV23,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,14,280,345.5,227.5,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,9V,181,237,138,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,18C,481,600.7,385.1,PPV23,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,3,49,56.9,42.9,PPV23,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,1,55,64.8,46.2,PPV23,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,5,72,86.6,59.7,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,19F,333,404.8,273.2,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,14,285,354.3,228.9,PPV23,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,4,545,672.3,441.9,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,18C,907,1080.1,761.9,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,5,36,43.1,29.5,PPV23,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,6B,1261,1552.6,1024.7,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,3,55,62.9,47.7,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,1,81,95.9,68.4,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,7F,245,312.4,191.9,PCV13,1m post dose 1 adult,1 dose adult,0
NCT00546572,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,Europe,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe,North America,North America,North America,North America,North America,Europe","[""Older Adult""]",1 month after Vax 1 / Year 0,OPA,1,19F,214,262.8,174.3,PPV23,1m post dose 1 adult,1 dose adult,0
NCT00475033,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,6B,2.16,2.49,1.87,PCV13,1m post primary child,3+1 child,0
NCT00475033,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,2,1.82,2.04,1.63,PCV13,1m post primary child,3+1 child,0
NCT00475033,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,23F,1.15,1.3,1.03,PCV13,1m post primary child,3+1 child,0
NCT00475033,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,14,5.43,6.06,4.86,PCV13,1m post primary child,3+1 child,0
NCT00475033,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,19F,2.18,2.39,1.99,PCV13,1m post primary child,3+1 child,0
NCT00475033,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,9V,1.12,1.22,1.03,PCV13,1m post primary child,3+1 child,0
NCT00475033,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,18C,1.37,1.52,1.23,PCV13,1m post primary child,3+1 child,0
NCT00475033,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,4,1.46,1.6,1.33,PCV13,1m post primary child,3+1 child,0
NCT00475033,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the 3-dose infant series (7 months of age),GMC,3,5,0.63,0.7,0.58,PCV13,1m post primary child,3+1 child,0
NCT00475033,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,9V,2.04,2.23,1.87,PCV13,1m post boost child,3+1 child,0
NCT00475033,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,6B,9.83,10.94,8.83,PCV13,1m post boost child,3+1 child,0
NCT00475033,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,4,2.67,2.92,2.43,PCV13,1m post boost child,3+1 child,0
NCT00475033,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,19F,5.7,6.42,5.06,PCV13,1m post boost child,3+1 child,0
NCT00475033,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,18C,2,2.21,1.8,PCV13,1m post boost child,3+1 child,0
NCT00475033,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,14,7.58,8.37,6.86,PCV13,1m post boost child,3+1 child,0
NCT00475033,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,23F,3.59,4.01,3.21,PCV13,1m post boost child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,5,0.88,1,0.77,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,7F,5.66,6.53,4.9,PCV13,1m post boost child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,23F,0.4,0.48,0.34,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,23F,1.67,1.94,1.44,PCV13,1m post primary child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,19F,2.98,3.41,2.6,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,19A,10.21,11.68,8.92,PCV13,1m post boost child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,19A,1.52,1.76,1.31,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,23F,3.96,4.59,3.43,PCV13,1m post boost child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,14,4.51,5.22,3.89,PCV13,1m post primary child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,3,0.85,0.95,0.76,PCV13,1m post primary child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,4,3.88,4.4,3.42,PCV13,1m post boost child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,1,1.87,2.16,1.61,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,1,4.6,5.37,3.94,PCV13,1m post boost child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,14,1.94,2.29,1.64,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,6B,0.21,0.25,0.18,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,9V,1.15,1.32,1.01,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,14,9.82,11.3,8.54,PCV13,1m post boost child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,19F,2.46,2.74,2.21,PCV13,1m post primary child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,5,3.69,4.18,3.26,PCV13,1m post boost child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,1,2.95,3.33,2.61,PCV13,1m post primary child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,7F,1.51,1.71,1.33,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,6B,2.59,3.05,2.2,PCV13,1m post primary child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,6A,7.71,8.8,6.75,PCV13,1m post boost child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,19F,6.11,7.16,5.21,PCV13,1m post boost child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,18C,1.3,1.51,1.11,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,4,2.32,2.6,2.08,PCV13,1m post primary child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,6A,3.08,3.44,2.76,PCV13,1m post primary child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,6A,0.81,0.95,0.7,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,4,1.55,1.78,1.35,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,5,1.83,2.06,1.62,PCV13,1m post primary child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,9V,2.67,3.05,2.34,PCV13,1m post boost child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,9V,1.51,1.68,1.35,PCV13,1m post primary child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,18C,1.86,2.07,1.68,PCV13,1m post primary child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,3,0.54,0.61,0.48,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,6B,12.25,13.92,10.78,PCV13,1m post boost child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,19A,2.5,2.75,2.27,PCV13,1m post primary child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,3,1.04,1.19,0.91,PCV13,1m post boost child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,7F,3.41,3.74,3.11,PCV13,1m post primary child,3+1 child,0
NCT00474539,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,18C,2.29,2.61,2.01,PCV13,1m post boost child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after toddler dose (13 months of age),GMC,4,3,5.1,5.92,4.39,PCV13,1m post boost child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after toddler dose (13 months of age),GMC,4,23F,4.27,4.98,3.66,PCV13,1m post boost child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after toddler dose (13 months of age),GMC,1,14,10.95,12.74,9.41,PCV7,1m post boost child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after toddler dose (13 months of age),GMC,4,6B,12.24,14.13,10.6,PCV13,1m post boost child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after toddler dose (13 months of age),GMC,1,4,5.85,6.68,5.13,PCV7,1m post boost child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after toddler dose (13 months of age),GMC,1,3,0.04,0.05,0.04,PCV7,1m post boost child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after toddler dose (13 months of age),GMC,1,9V,3.33,3.75,2.96,PCV7,1m post boost child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after toddler dose (13 months of age),GMC,4,14,10.59,12.18,9.21,PCV13,1m post boost child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after toddler dose (13 months of age),GMC,4,18C,2.63,2.97,2.33,PCV13,1m post boost child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after toddler dose (13 months of age),GMC,1,23F,5.31,6.04,4.66,PCV7,1m post boost child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after toddler dose (13 months of age),GMC,4,19F,8.38,9.87,7.11,PCV13,1m post boost child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after toddler dose (13 months of age),GMC,4,9V,3.01,3.37,2.68,PCV13,1m post boost child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after toddler dose (13 months of age),GMC,1,18C,2.98,3.34,2.65,PCV7,1m post boost child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after toddler dose (13 months of age),GMC,1,6B,11.6,13.53,9.95,PCV7,1m post boost child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after toddler dose (13 months of age),GMC,1,19F,5.65,6.58,4.84,PCV7,1m post boost child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after toddler dose (13 months of age),GMC,4,4,5.33,6.04,4.69,PCV13,1m post boost child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after the 3-dose infant series (18 weeks of age),GMC,1,6B,1.56,1.89,1.28,PCV7,1m post primary child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after the 3-dose infant series (18 weeks of age),GMC,3,14,2.84,3.43,2.35,PCV13,1m post primary child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after the 3-dose infant series (18 weeks of age),GMC,3,6B,1.45,1.75,1.2,PCV13,1m post primary child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after the 3-dose infant series (18 weeks of age),GMC,1,14,2.39,2.9,1.98,PCV7,1m post primary child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after the 3-dose infant series (18 weeks of age),GMC,3,18C,1.61,1.82,1.42,PCV13,1m post primary child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after the 3-dose infant series (18 weeks of age),GMC,1,9V,1.46,1.65,1.28,PCV7,1m post primary child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after the 3-dose infant series (18 weeks of age),GMC,3,4,2.19,2.46,1.95,PCV13,1m post primary child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after the 3-dose infant series (18 weeks of age),GMC,3,23F,1.38,1.6,1.18,PCV13,1m post primary child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after the 3-dose infant series (18 weeks of age),GMC,3,9V,1.34,1.5,1.19,PCV13,1m post primary child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after the 3-dose infant series (18 weeks of age),GMC,1,5,0.03,0.04,0.03,PCV7,1m post primary child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after the 3-dose infant series (18 weeks of age),GMC,3,5,1.95,2.22,1.72,PCV13,1m post primary child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after the 3-dose infant series (18 weeks of age),GMC,1,18C,1.7,1.96,1.47,PCV7,1m post primary child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after the 3-dose infant series (18 weeks of age),GMC,1,23F,1.46,1.7,1.25,PCV7,1m post primary child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after the 3-dose infant series (18 weeks of age),GMC,1,19F,2.47,2.89,2.11,PCV7,1m post primary child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after the 3-dose infant series (18 weeks of age),GMC,3,19F,2.25,2.56,1.97,PCV13,1m post primary child,3+1 child,0
NCT00452790,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",1 month after the 3-dose infant series (18 weeks of age),GMC,1,4,2.58,2.95,2.26,PCV7,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,19F,4.67,5.14,4.23,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,8,11.14,12.11,10.24,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,23F,3.46,3.82,3.14,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,14,6.61,7.22,6.06,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,23F,3.1,3.43,2.81,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,18C,2.2,2.41,2.01,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,5,3.06,3.35,2.79,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,8,9.33,10.19,8.55,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,5,2.29,2.48,2.11,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,5,2.25,2.44,2.07,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,14,6.91,7.56,6.32,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,9V,1.99,2.15,1.84,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,23F,3.35,3.71,3.02,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,18C,1.95,2.12,1.78,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,9V,1.95,2.1,1.8,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,8,9.92,10.75,9.15,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,19F,4.51,5.03,4.05,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,14,7.05,7.74,6.42,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,19F,6.51,7.18,5.91,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,18C,2.48,2.71,2.27,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 month after the toddler dose (13 months of age),GMC,4,9V,1.91,2.06,1.76,PCV13,1m post boost child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,14,5.18,5.69,4.72,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,9V,1.05,1.12,0.98,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,18C,1.48,1.58,1.38,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,6B,2.89,3.23,2.58,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,9V,1.11,1.19,1.04,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,4,0.61,0.66,0.57,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,23F,1.27,1.4,1.15,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,14,5.13,5.59,4.7,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,19F,1.85,1.99,1.71,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,5,1.62,1.76,1.5,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,18C,1.34,1.44,1.24,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,8,1.75,1.88,1.63,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,4,0.52,0.55,0.48,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,5,1.91,2.07,1.76,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,9V,1.11,1.19,1.04,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,8,1.33,1.43,1.24,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,19F,2.07,2.24,1.92,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,6B,2.15,2.42,1.91,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,23F,1.24,1.36,1.13,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,19F,2.59,2.78,2.4,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,6B,2.54,2.85,2.27,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,18C,1.3,1.38,1.22,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,23F,1.03,1.14,0.94,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,14,4.97,5.37,4.59,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,5,1.81,1.98,1.66,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,4,0.56,0.61,0.52,PCV13,1m post primary child,3+1 child,0
NCT00444457,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month after the infant series (7 Months of age),GMC,3,8,1.34,1.44,1.25,PCV13,1m post primary child,3+1 child,0
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,19F,1533,1680.9,1397.3,PCV13,1m post dose 1 adult,1 dose adult,936
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,5,199,242.3,164,PCV13,1m post dose 1 adult,1 dose adult,3120
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,23F,1570,1770.2,1392.8,PCV13,1m post dose 1 adult,1 dose adult,936
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,5,269,332.5,218.1,PCV13,1m post dose 1 adult,1 dose adult,2600
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,19A,956,1090.7,837.6,PCV13,1m post dose 1 adult,1 dose adult,2600
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,14,2983,3246.6,2740.5,PCV13,1m post dose 1 adult,1 dose adult,936
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,19F,599,731,491,PCV13,1m post dose 1 adult,1 dose adult,2600
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,9V,3339,3670.4,3037.4,PCV13,1m post dose 1 adult,1 dose adult,936
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,14,957,1174.5,779.6,PCV13,1m post dose 1 adult,1 dose adult,2600
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,7F,1520,1812.1,1274.5,PCV13,1m post dose 1 adult,1 dose adult,2600
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,6A,5746,6300.4,5240.7,PCV13,1m post dose 1 adult,1 dose adult,936
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,3,91,104.7,79.9,PCV13,1m post dose 1 adult,1 dose adult,2600
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,3,93,106.6,81.1,PCV13,1m post dose 1 adult,1 dose adult,3120
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,6B,1984,2453.6,1604,PCV13,1m post dose 1 adult,1 dose adult,3120
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,19A,1580,1696.3,1471.4,PCV13,1m post dose 1 adult,1 dose adult,936
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,6A,2593,3131.1,2146.7,PCV13,1m post dose 1 adult,1 dose adult,3120
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,1,146,172.9,124,PCV13,1m post dose 1 adult,1 dose adult,3120
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,1,353,386.9,322.8,PCV13,1m post dose 1 adult,1 dose adult,936
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,4,4747,5155.5,4370.2,PCV13,1m post dose 1 adult,1 dose adult,936
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,23F,375,472.6,297.2,PCV13,1m post dose 1 adult,1 dose adult,3120
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,3,91,98.4,84.2,PCV13,1m post dose 1 adult,1 dose adult,936
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,14,612,764.2,489.6,PCV13,1m post dose 1 adult,1 dose adult,3120
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,19A,682,779.9,596.5,PCV13,1m post dose 1 adult,1 dose adult,3120
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,9V,1726,2086.2,1428.5,PCV13,1m post dose 1 adult,1 dose adult,2600
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,18C,3989,4383.8,3629.4,PCV13,1m post dose 1 adult,1 dose adult,936
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,19F,517,635.3,420.8,PCV13,1m post dose 1 adult,1 dose adult,3120
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,7F,1120,1382.9,907.6,PCV13,1m post dose 1 adult,1 dose adult,3120
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,4,2062,2510.5,1693.6,PCV13,1m post dose 1 adult,1 dose adult,3120
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,1,200,236,170.3,PCV13,1m post dose 1 adult,1 dose adult,2600
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,9V,1164,1448.3,934.8,PCV13,1m post dose 1 adult,1 dose adult,3120
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,18C,1939,2350.2,1599.2,PCV13,1m post dose 1 adult,1 dose adult,2600
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,7F,3249,3523.9,2994.8,PCV13,1m post dose 1 adult,1 dose adult,936
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,4,2833,3327.4,2412.1,PCV13,1m post dose 1 adult,1 dose adult,2600
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,6B,3212,3781.4,2728.6,PCV13,1m post dose 1 adult,1 dose adult,2600
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,6B,9813,10583.5,9097.8,PCV13,1m post dose 1 adult,1 dose adult,936
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,23F,494,630.7,386.8,PCV13,1m post dose 1 adult,1 dose adult,2600
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,6A,4328,5121.5,3658.1,PCV13,1m post dose 1 adult,1 dose adult,2600
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,5,386,435.8,342.6,PCV13,1m post dose 1 adult,1 dose adult,936
NCT00427895,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Adult""]",One month after vaccination 1,OPA,1,18C,1726,2082.9,1429.7,PCV13,1m post dose 1 adult,1 dose adult,3120
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month After the Toddler Dose,GMC,4,19F,6.6,7.44,5.85,PCV13,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month After the Toddler Dose,GMC,4,5,5.49,6.13,4.91,PCV7,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month After the Toddler Dose,GMC,4,14,12.72,14.41,11.22,PCV7,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month After the Toddler Dose,GMC,4,23F,7.84,8.9,6.91,PCV7,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month After the Toddler Dose,GMC,4,18C,4.7,5.28,4.18,PCV7,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month After the Toddler Dose,GMC,4,18C,3.2,3.64,2.82,PCV13,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month After the Toddler Dose,GMC,4,6B,11.53,13.3,9.99,PCV13,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month After the Toddler Dose,GMC,4,23F,5.07,5.83,4.41,PCV13,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month After the Toddler Dose,GMC,4,5,3.73,4.24,3.28,PCV13,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month After the Toddler Dose,GMC,4,14,9.11,10.45,7.95,PCV13,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month After the Toddler Dose,GMC,4,6B,15.63,17.69,13.8,PCV7,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month After the Toddler Dose,GMC,4,19F,5.6,6.43,4.87,PCV7,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month After the Toddler Dose,GMC,4,9V,2.62,2.94,2.32,PCV13,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",1 Month After the Toddler Dose,GMC,4,9V,3.63,4.05,3.25,PCV7,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,3,19F,44.92,59.52,33.9,PCV7,1m post primary child,3+1 child,28
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,4,23F,4981.68,6386.76,3885.71,PCV7,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,4,6B,4066.22,5097.76,3243.42,PCV7,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,3,23F,791.07,1034.44,604.96,PCV13,1m post primary child,1 dose adult,28
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,4,9V,11856.03,15955.49,8809.85,PCV13,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,3,6B,1513.66,1898.81,1206.64,PCV7,1m post primary child,3+1 child,28
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,4,9V,18032.33,23020.53,14124.99,PCV7,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,3,14,1240.41,1645.69,934.93,PCV13,1m post primary child,1 dose adult,28
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,3,18C,275.59,361.1,210.33,PCV13,1m post primary child,1 dose adult,28
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,4,8,1492.46,1998.78,1114.4,PCV7,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,3,9V,4035.4,5552.75,2932.68,PCV13,1m post primary child,1 dose adult,28
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,3,6B,1054.65,1360.87,817.34,PCV13,1m post primary child,1 dose adult,28
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,3,23F,923.56,1203.74,708.59,PCV7,1m post primary child,3+1 child,28
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,4,18C,993.27,1308.33,754.08,PCV13,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,4,18C,1722.16,2235.67,1326.59,PCV7,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,4,23F,2723.25,3782.41,1960.67,PCV13,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,4,6B,3099.51,4110.79,2337.02,PCV13,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,3,19F,54.42,73.65,40.2,PCV13,1m post primary child,1 dose adult,28
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,4,14,2002.23,2759.93,1452.54,PCV13,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,4,8,1179.98,1643.2,847.34,PCV13,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,3,8,535.68,681.37,421.13,PCV7,1m post primary child,3+1 child,28
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,3,9V,3259.01,4641.25,2288.43,PCV7,1m post primary child,3+1 child,28
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,4,14,2365.87,2992.34,1870.56,PCV7,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,3,14,1480.55,1934.02,1133.4,PCV7,1m post primary child,3+1 child,28
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,3,18C,375.64,483.75,291.68,PCV7,1m post primary child,3+1 child,28
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,4,19F,199.65,276.38,144.22,PCV13,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,4,19F,167.2,230.37,121.35,PCV7,1m post boost child,3+1 child,64
NCT00373958,Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",one month after the infant series and the toddler dose,OPA,3,8,359.32,467.72,276.04,PCV13,1m post primary child,1 dose adult,28
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,8,3.88,4.41,3.41,PCV13,1m post primary child,3+1 child,28
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,18C,1.58,1.78,1.4,PCV13,1m post 2nd primary dose child,3+1 child,20
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,4,4.97,5.58,4.42,PCV13,1m post boost child,3+1 child,64
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,14,3.84,4.37,3.37,PCV13,1m post 2nd primary dose child,3+1 child,20
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,23F,0.54,0.62,0.47,PCV13,1m post 2nd primary dose child,3+1 child,20
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,8,0.42,0.47,0.37,PCV13,1m post 2nd primary dose child,3+1 child,20
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,23F,2.15,2.45,1.89,PCV13,1m post primary child,3+1 child,28
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,19F,2.64,2.89,2.42,PCV13,1m post primary child,3+1 child,28
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,8,11.88,13.35,10.57,PCV13,1m post boost child,3+1 child,64
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,4,1.89,2.1,1.7,PCV13,1m post 2nd primary dose child,3+1 child,20
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,18C,2.29,2.52,2.08,PCV13,1m post primary child,3+1 child,28
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,19F,2.85,3.21,2.53,PCV7,1m post 2nd primary dose child,3+1 child,20
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,18C,3.96,4.43,3.55,PCV13,1m post boost child,3+1 child,64
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,2,9V,1.49,1.66,1.34,PCV13,1m post 2nd primary dose child,3+1 child,20
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,4,2.33,2.57,2.11,PCV13,1m post primary child,3+1 child,28
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,14,6.17,6.98,5.45,PCV13,1m post primary child,3+1 child,28
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,3,9V,1.71,1.86,1.56,PCV13,1m post primary child,3+1 child,28
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,14,11.37,12.71,10.17,PCV13,1m post boost child,3+1 child,64
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,23F,5.07,5.71,4.5,PCV13,1m post boost child,3+1 child,64
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,19F,8.04,9.14,7.07,PCV13,1m post boost child,3+1 child,64
NCT00368966,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (at 5 months of age) and dose 3 (at 7 months of age) and one month after the toddler dose (at 16 months of age),GMC,4,9V,3.44,3.8,3.12,PCV13,1m post boost child,3+1 child,64
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,2,5,127.11,162.6,99.36,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,2,6B,191.34,274.55,133.35,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,2,14,1882.96,2451.1,1446.51,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,2,4,526.69,642.32,431.88,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,3,6A,2217.29,2698.42,1821.95,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,2,6A,541.81,748.68,392.09,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,3,4,1276.21,1588.85,1025.09,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,3,1,294.07,381.15,226.88,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,2,3,176.07,213.96,144.89,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,2,19F,222.86,291.37,170.46,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,3,23F,3679.67,4556.44,2971.61,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,3,3,504.66,584.53,435.71,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,3,9V,16384,20543.06,13066.97,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,2,1,62.63,82.41,47.59,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,3,7F,14886.35,17643.22,12560.25,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,3,14,1903.89,2292.88,1580.9,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,3,18C,1324.41,1649.22,1063.57,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,2,18C,294.48,390.98,221.8,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,3,6B,2383.31,3069.57,1850.47,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,3,5,333.24,404.94,274.24,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,2,9V,3585.8,4612.99,2787.34,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,2,7F,5914.33,7425.3,4710.83,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,2,23F,487.51,667.13,356.25,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",one month after infant series dose 2 and after the toddler dose,OPA,3,19F,391.97,518.46,296.34,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after toddler dose (12 months of age),GMC,3,23F,4.87,5.51,4.3,PCV7,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after toddler dose (12 months of age),GMC,3,5,7.08,7.83,6.41,PCV7,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after toddler dose (12 months of age),GMC,3,4,0.03,0.04,0.03,PCV7,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after toddler dose (12 months of age),GMC,3,19F,9.01,10.36,7.84,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after toddler dose (12 months of age),GMC,3,4,5.76,6.47,5.12,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after toddler dose (12 months of age),GMC,3,19F,8.06,9.21,7.06,PCV7,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after toddler dose (12 months of age),GMC,3,6B,10.39,11.82,9.14,PCV7,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after toddler dose (12 months of age),GMC,3,6B,10,11.38,8.79,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after toddler dose (12 months of age),GMC,3,18C,2.83,3.14,2.55,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after toddler dose (12 months of age),GMC,3,9V,3.02,3.32,2.74,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after toddler dose (12 months of age),GMC,3,18C,4.26,4.7,3.85,PCV7,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after toddler dose (12 months of age),GMC,3,14,11.99,13.35,10.77,PCV7,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after toddler dose (12 months of age),GMC,3,14,10.3,11.47,9.26,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after toddler dose (12 months of age),GMC,3,9V,4.1,4.51,3.72,PCV7,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after toddler dose (12 months of age),GMC,3,23F,3.43,3.88,3.02,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after toddler dose (12 months of age),GMC,3,5,4.77,5.3,4.29,PCV13,1m post boost child,2+1 child,52
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,19F,3.42,3.97,2.95,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,18C,0.35,0.39,0.32,PCV13,pre-boost child,2+1 child,48
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,6B,0.61,0.69,0.54,PCV13,pre-boost child,2+1 child,48
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,3,1.15,1.28,1.04,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,23F,0.61,0.71,0.53,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,6A,0.81,0.92,0.72,PCV13,pre-boost child,2+1 child,48
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,23F,0.26,0.29,0.23,PCV13,pre-boost child,2+1 child,48
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,7F,0.76,0.82,0.7,PCV13,pre-boost child,2+1 child,48
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,4,0.53,0.59,0.48,PCV13,pre-boost child,2+1 child,48
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,1,2.3,2.6,2.03,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,19F,0.94,1.06,0.83,PCV13,pre-boost child,2+1 child,48
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,4,2.38,2.67,2.11,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,5,0.88,0.97,0.8,PCV13,pre-boost child,2+1 child,48
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,7F,2.06,2.26,1.88,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,6A,1.17,1.33,1.02,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,5,1.27,1.41,1.14,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,14,2.03,2.3,1.79,PCV13,pre-boost child,2+1 child,48
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,3,0.25,0.27,0.22,PCV13,pre-boost child,2+1 child,48
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,14,2.84,3.31,2.44,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,18C,1.72,1.93,1.54,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,9V,1.68,1.86,1.51,PCV13,1m post primary child,2+1 child,24
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,1,0.68,0.75,0.61,PCV13,pre-boost child,2+1 child,48
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,9V,0.48,0.52,0.43,PCV13,pre-boost child,2+1 child,48
NCT00366899,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after infant series dose 2 (6 months of age) and before the toddler dose (11 months of age),GMC,2,6B,0.41,0.47,0.36,PCV13,1m post primary child,2+1 child,24
NCT00366678,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after the toddler dose (at 13 months of age),OPA,4,1,126,158.97,99.87,PCV13,1m post boost child,3+1 child,56
NCT00366678,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after the toddler dose (at 13 months of age),OPA,4,5,244.18,297.92,200.14,PCV13,1m post boost child,3+1 child,56
NCT00366678,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after the toddler dose (at 13 months of age),OPA,4,7F,8126.24,9919.21,6657.36,PCV13,1m post boost child,3+1 child,56
NCT00366678,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after the toddler dose (at 13 months of age),OPA,4,19A,804.06,1049.71,615.9,PCV13,1m post boost child,3+1 child,56
NCT00366678,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after the toddler dose (at 13 months of age),OPA,4,3,345.33,402.8,296.06,PCV13,1m post boost child,3+1 child,56
NCT00366678,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after the toddler dose (at 13 months of age),OPA,4,6A,1346.83,1585.65,1143.98,PCV13,1m post boost child,3+1 child,56
NCT00366678,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after the 3-Dose Infant Series (at 5 months of age),GMC,3,14,2.74,3.16,2.38,PCV13,1m post primary child,3+1 child,20
NCT00366678,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after the 3-Dose Infant Series (at 5 months of age),GMC,3,23F,0.92,1.06,0.8,PCV13,1m post primary child,3+1 child,20
NCT00366678,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after the 3-Dose Infant Series (at 5 months of age),GMC,3,4,1.29,1.46,1.14,PCV13,1m post primary child,3+1 child,20
NCT00366678,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after the 3-Dose Infant Series (at 5 months of age),GMC,3,6B,0.74,0.89,0.62,PCV13,1m post primary child,3+1 child,20
NCT00366678,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after the 3-Dose Infant Series (at 5 months of age),GMC,3,19F,1.55,1.7,1.42,PCV13,1m post primary child,3+1 child,20
NCT00366678,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after the 3-Dose Infant Series (at 5 months of age),GMC,3,9V,1.15,1.28,1.03,PCV13,1m post primary child,3+1 child,20
NCT00366678,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after the 3-Dose Infant Series (at 5 months of age),GMC,3,18C,1.42,1.6,1.26,PCV13,1m post primary child,3+1 child,20
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one mone month after 3-dose infant series (at 7 months of age),GMC,3,7F,5.78,6.45,5.19,PCV13,1m post primary child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one mone month after 3-dose infant series (at 7 months of age),GMC,3,18C,3.68,4.14,3.27,PCV13,1m post primary child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one mone month after 3-dose infant series (at 7 months of age),GMC,3,23F,2.57,3,2.21,PCV13,1m post primary child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one mone month after 3-dose infant series (at 7 months of age),GMC,3,9V,3.39,3.78,3.03,PCV13,1m post primary child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one mone month after 3-dose infant series (at 7 months of age),GMC,3,6B,4.77,5.59,4.07,PCV13,1m post primary child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one mone month after 3-dose infant series (at 7 months of age),GMC,3,4,6.76,7.59,6.02,PCV13,1m post primary child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one mone month after 3-dose infant series (at 7 months of age),GMC,3,3,2.87,3.24,2.55,PCV13,1m post primary child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one mone month after 3-dose infant series (at 7 months of age),GMC,3,19F,5.71,6.65,4.9,PCV13,1m post primary child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one mone month after 3-dose infant series (at 7 months of age),GMC,3,5,3.85,4.33,3.42,PCV13,1m post primary child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one mone month after 3-dose infant series (at 7 months of age),GMC,3,14,14.69,16.26,13.26,PCV13,1m post primary child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one mone month after 3-dose infant series (at 7 months of age),GMC,3,1,5.11,5.82,4.48,PCV13,1m post primary child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one mone month after 3-dose infant series (at 7 months of age),GMC,3,19A,6.97,7.77,6.25,PCV13,1m post primary child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one mone month after 3-dose infant series (at 7 months of age),GMC,3,6A,3.77,4.25,3.35,PCV13,1m post primary child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one month after the toddler dose (at 12-15 months of age),GMC,4,18C,6.09,6.95,5.34,PCV13,1m post boost child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one month after the toddler dose (at 12-15 months of age),GMC,4,3,2.06,2.32,1.83,PCV13,1m post boost child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one month after the toddler dose (at 12-15 months of age),GMC,4,6B,14.61,17.05,12.52,PCV13,1m post boost child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one month after the toddler dose (at 12-15 months of age),GMC,4,9V,4.49,5.06,4,PCV13,1m post boost child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one month after the toddler dose (at 12-15 months of age),GMC,4,23F,6.55,7.75,5.53,PCV13,1m post boost child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one month after the toddler dose (at 12-15 months of age),GMC,4,6A,11.03,12.55,9.69,PCV13,1m post boost child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one month after the toddler dose (at 12-15 months of age),GMC,4,4,9.7,11.17,8.43,PCV13,1m post boost child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one month after the toddler dose (at 12-15 months of age),GMC,4,14,16.33,18.41,14.49,PCV13,1m post boost child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one month after the toddler dose (at 12-15 months of age),GMC,4,5,7.31,8.2,6.52,PCV13,1m post boost child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one month after the toddler dose (at 12-15 months of age),GMC,4,19A,15.97,18.13,14.07,PCV13,1m post boost child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one month after the toddler dose (at 12-15 months of age),GMC,4,1,9.85,11.27,8.62,PCV13,1m post boost child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one month after the toddler dose (at 12-15 months of age),GMC,4,19F,12.2,14.35,10.37,PCV13,1m post boost child,3+1 child,0
NCT00574795,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia,Asia","[""Child""]",one month after the toddler dose (at 12-15 months of age),GMC,4,7F,8.31,9.35,7.39,PCV13,1m post boost child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 3 of infant series (6 months of age),GMC,3,18C,2.5,2.81,2.23,PCV13,1m post primary child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 3 of infant series (6 months of age),GMC,3,7F,3.71,4.12,3.34,PCV13,1m post primary child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 3 of infant series (6 months of age),GMC,3,19F,3.75,4.29,3.28,PCV13,1m post primary child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 3 of infant series (6 months of age),GMC,3,9V,2.34,2.6,2.11,PCV13,1m post primary child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 3 of infant series (6 months of age),GMC,3,19A,4.19,4.74,3.71,PCV13,1m post primary child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 3 of infant series (6 months of age),GMC,3,1,4.23,4.79,3.73,PCV13,1m post primary child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 3 of infant series (6 months of age),GMC,3,6A,4.08,4.68,3.56,PCV13,1m post primary child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 3 of infant series (6 months of age),GMC,3,3,1.17,1.33,1.03,PCV13,1m post primary child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 3 of infant series (6 months of age),GMC,3,6B,5.02,5.9,4.27,PCV13,1m post primary child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 3 of infant series (6 months of age),GMC,3,5,3.11,3.52,2.75,PCV13,1m post primary child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 3 of infant series (6 months of age),GMC,3,4,3.48,3.88,3.12,PCV13,1m post primary child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 3 of infant series (6 months of age),GMC,3,23F,1.83,2.17,1.55,PCV13,1m post primary child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 3 of infant series (6 months of age),GMC,3,14,9.35,10.82,8.07,PCV13,1m post primary child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Toddler Dose (12 months of age),GMC,4,5,4.75,5.4,4.18,PCV13,1m post boost child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Toddler Dose (12 months of age),GMC,4,19A,8.95,10.23,7.84,PCV13,1m post boost child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Toddler Dose (12 months of age),GMC,4,1,5.86,6.75,5.08,PCV13,1m post boost child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Toddler Dose (12 months of age),GMC,4,6A,11.64,13.64,9.93,PCV13,1m post boost child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Toddler Dose (12 months of age),GMC,4,7F,5.81,6.51,5.18,PCV13,1m post boost child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Toddler Dose (12 months of age),GMC,4,18C,3.93,4.48,3.45,PCV13,1m post boost child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Toddler Dose (12 months of age),GMC,4,23F,5.7,6.77,4.81,PCV13,1m post boost child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Toddler Dose (12 months of age),GMC,4,4,5.1,5.89,4.41,PCV13,1m post boost child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Toddler Dose (12 months of age),GMC,4,14,10.62,12.32,9.16,PCV13,1m post boost child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Toddler Dose (12 months of age),GMC,4,9V,3.76,4.29,3.29,PCV13,1m post boost child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Toddler Dose (12 months of age),GMC,4,6B,15.41,18.38,12.92,PCV13,1m post boost child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Toddler Dose (12 months of age),GMC,4,3,1.62,1.84,1.42,PCV13,1m post boost child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Toddler Dose (12 months of age),GMC,4,19F,11.33,13.26,9.68,PCV13,1m post boost child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 2 of infant series (4 months of age),GMC,2,23F,0.84,0.99,0.71,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 2 of infant series (4 months of age),GMC,2,7F,2.98,3.29,2.7,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 2 of infant series (4 months of age),GMC,2,6A,1.86,2.16,1.6,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 2 of infant series (4 months of age),GMC,2,14,5.54,6.5,4.72,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 2 of infant series (4 months of age),GMC,2,1,3.41,3.89,3,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 2 of infant series (4 months of age),GMC,2,19F,4.14,4.78,3.59,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 2 of infant series (4 months of age),GMC,2,5,1.89,2.13,1.67,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 2 of infant series (4 months of age),GMC,2,4,3.54,3.97,3.16,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 2 of infant series (4 months of age),GMC,2,18C,1.8,2.07,1.56,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 2 of infant series (4 months of age),GMC,2,3,1.11,1.23,1.01,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 2 of infant series (4 months of age),GMC,2,19A,3.52,4.03,3.07,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 2 of infant series (4 months of age),GMC,2,9V,1.82,2.08,1.6,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00708682,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",Dose 2 of infant series (4 months of age),GMC,2,6B,0.84,0.98,0.71,PCV13,1m post 2nd primary dose child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,8,4.25,4.75,3.8,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,19F,5.99,6.68,5.36,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,23F,3.36,3.78,2.98,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,9V,2.75,2.99,2.52,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,6B,9.14,10.26,8.14,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,23F,3.36,3.78,2.98,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,18C,2.79,3.07,2.53,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,8,0.52,0.57,0.48,PCV13,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,14,2.65,3,2.34,PCV7,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,8,0.52,0.57,0.48,PCV13,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,19F,0.68,0.76,0.6,PCV13,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,23F,4.33,5,3.75,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,19F,4.72,5.41,4.12,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,4,0.46,0.51,0.42,PCV13,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,18C,3.44,3.84,3.08,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,8,0.03,0.03,0.02,PCV7,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,8,0.03,0.04,0.03,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,14,11.01,12.29,9.87,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,18C,0.39,0.43,0.36,PCV7,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,6B,9.85,11.22,8.66,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,14,8.34,9.28,7.5,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,4,0.58,0.64,0.53,PCV7,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,19F,0.58,0.66,0.52,PCV7,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,9V,0.52,0.57,0.48,PCV7,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,18C,3.44,3.84,3.08,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,4,4.16,4.62,3.75,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,4,5.07,5.67,4.53,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,6B,1.06,1.2,0.94,PCV7,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,4,0.58,0.64,0.53,PCV7,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,18C,0.39,0.43,0.36,PCV7,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,19F,5.99,6.68,5.36,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,6B,9.14,10.26,8.14,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,8,0.03,0.04,0.03,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,6B,0.97,1.07,0.87,PCV13,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,18C,0.33,0.36,0.3,PCV13,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,14,2.2,2.48,1.96,PCV13,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,19F,0.68,0.76,0.6,PCV13,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,19F,0.58,0.66,0.52,PCV7,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,9V,0.46,0.5,0.42,PCV13,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,8,4.25,4.75,3.8,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,14,8.34,9.28,7.5,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,4,4.16,4.62,3.75,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,14,2.65,3,2.34,PCV7,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,14,2.2,2.48,1.96,PCV13,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,6B,0.97,1.07,0.87,PCV13,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,9V,0.52,0.57,0.48,PCV7,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,23F,0.39,0.45,0.34,PCV7,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,6B,9.85,11.22,8.66,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,14,11.01,12.29,9.87,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,23F,4.33,5,3.75,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,6B,1.06,1.2,0.94,PCV7,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,23F,0.39,0.45,0.34,PCV7,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,8,0.03,0.03,0.02,PCV7,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,18C,0.33,0.36,0.3,PCV13,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,23F,0.33,0.37,0.3,PCV13,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,9V,3.36,3.73,3.02,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,4,0.46,0.51,0.42,PCV13,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,4,5.07,5.67,4.53,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,9V,0.46,0.5,0.42,PCV13,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,19F,4.72,5.41,4.12,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,18C,2.79,3.07,2.53,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,9V,2.75,2.99,2.52,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,4,9V,3.36,3.73,3.02,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,23F,0.33,0.37,0.3,PCV13,pre-boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after the Toddler Dose (13 to 16 months of age),OPA,4,6A,599.9,957.54,375.83,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after the Toddler Dose (13 to 16 months of age),OPA,4,6A,2147.58,2828.23,1630.73,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after the Toddler Dose (13 to 16 months of age),OPA,4,19A,802.24,1015.24,633.92,PCV13,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after the Toddler Dose (13 to 16 months of age),OPA,4,19A,36.62,63.59,21.09,PCV7,1m post boost child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,1,1.83,2.04,1.64,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,19F,2.86,3.24,2.53,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,9V,1.52,1.78,1.29,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,8,0.06,0.09,0.05,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,6B,2.86,3.91,2.09,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,6A,0.23,0.26,0.2,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,6A,1.33,1.49,1.18,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,3,0.05,0.06,0.04,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,23F,1.81,2.19,1.51,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,5,0.2,0.23,0.18,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,18C,1.53,1.8,1.3,PCV13,1m post primary child,3+1 child,28
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,14,4.14,4.66,3.68,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,9V,1.96,2.17,1.77,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,23F,1.39,1.67,1.15,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,9V,1.78,2.05,1.55,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,18C,2.25,2.49,2.04,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,6A,0.23,0.26,0.2,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,9V,1.52,1.78,1.29,PCV13,1m post primary child,3+1 child,28
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,18C,2.46,2.91,2.08,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,23F,1.44,1.65,1.25,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,9V,1.78,2.05,1.55,PCV7,1m post primary child,3+1 child,28
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,9V,1.78,2.05,1.55,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,6B,1.49,1.75,1.27,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,14,5.19,6.52,4.13,PCV7,1m post primary child,3+1 child,28
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,8,0.06,0.09,0.05,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,5,0.2,0.23,0.18,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,14,5.19,6.52,4.13,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,23F,1.44,1.65,1.25,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,18C,2.25,2.49,2.04,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,7F,2.59,2.85,2.36,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,19A,0.64,0.71,0.58,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,7F,0.04,0.05,0.04,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,8,2.57,3.08,2.14,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,19F,2.58,3.08,2.17,PCV7,1m post primary child,3+1 child,28
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,18C,2.46,2.91,2.08,PCV7,1m post primary child,3+1 child,28
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,4,1.81,2.13,1.54,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,23F,1.81,2.19,1.51,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,9V,1.96,2.17,1.77,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,8,0.06,0.09,0.05,PCV7,1m post primary child,3+1 child,28
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,19F,2.21,2.61,1.87,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,14,4.61,5.23,4.07,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,4,2.4,2.87,2.01,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,4,2.4,2.87,2.01,PCV7,1m post primary child,3+1 child,28
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,5,1.31,1.46,1.17,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,1,0.03,0.03,0.02,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,19F,2.86,3.24,2.53,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,23F,1.81,2.19,1.51,PCV7,1m post primary child,3+1 child,28
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,1,0.03,0.03,0.02,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,18C,2.46,2.91,2.08,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,7F,0.04,0.05,0.04,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,3,0.05,0.06,0.04,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,19A,3.26,3.59,2.97,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,6B,2.86,3.91,2.09,PCV7,1m post primary child,3+1 child,28
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,6B,0.98,1.14,0.84,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,19A,0.64,0.71,0.58,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,19F,2.21,2.61,1.87,PCV13,1m post primary child,3+1 child,28
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,4,1.81,2.13,1.54,PCV13,1m post primary child,3+1 child,28
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,4,2.99,3.33,2.68,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,19F,1.73,1.92,1.56,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,23F,1.26,1.43,1.11,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,19F,2.21,2.61,1.87,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,14,4.14,4.66,3.68,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,18C,1.94,2.14,1.76,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,19F,2.58,3.08,2.17,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,19F,2.58,3.08,2.17,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,4,2.18,2.4,1.98,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,6B,1.49,1.75,1.27,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,6B,0.98,1.14,0.84,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,3,1.55,1.72,1.41,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,19F,1.73,1.92,1.56,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,9V,1.65,1.8,1.51,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,4,2.4,2.87,2.01,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,18C,1.53,1.8,1.3,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,7F,2.59,2.85,2.36,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,14,5.19,6.52,4.13,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,5,1.31,1.46,1.17,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,18C,1.94,2.14,1.76,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,1,1.83,2.04,1.64,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,4,2.99,3.33,2.68,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,8,2.57,3.08,2.14,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,19A,3.26,3.59,2.97,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,6B,2.86,3.91,2.09,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,9V,1.52,1.78,1.29,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,14,4.24,5.23,3.44,PCV13,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,14,4.61,5.23,4.07,PCV7,1m post primary child,3+1 child,0
NCT00205803,Wyeth is now a wholly owned subsidiary of Pfizer,"Phase 1, Phase 2",North America,"[""Child""]",One month after 3-dose infant series (at 7 months of age),GMC,3,6B,2.74,3.71,2.02,PCV13,1m post primary child,3+1 child,0
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,8,0.52,0.57,0.48,PCV13,pre-boost child,3+1 child,52
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,23F,0.33,0.37,0.3,PCV13,pre-boost child,3+1 child,52
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,9V,0.46,0.5,0.42,PCV13,pre-boost child,3+1 child,52
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,19F,0.58,0.66,0.52,PCV7,pre-boost child,3+1 child,52
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,4,0.58,0.64,0.53,PCV7,pre-boost child,3+1 child,52
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,14,2.2,2.48,1.96,PCV13,pre-boost child,3+1 child,52
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,6B,0.97,1.07,0.87,PCV13,pre-boost child,3+1 child,52
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,19F,0.68,0.76,0.6,PCV13,pre-boost child,3+1 child,52
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,23F,0.39,0.45,0.34,PCV7,pre-boost child,3+1 child,52
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,14,2.65,3,2.34,PCV7,pre-boost child,3+1 child,52
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,4,0.46,0.51,0.42,PCV13,pre-boost child,3+1 child,52
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,18C,0.33,0.36,0.3,PCV13,pre-boost child,3+1 child,52
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,8,0.03,0.03,0.02,PCV7,pre-boost child,3+1 child,52
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,6B,1.06,1.2,0.94,PCV7,pre-boost child,3+1 child,52
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,9V,0.52,0.57,0.48,PCV7,pre-boost child,3+1 child,52
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",Immediately before (12 months of age) and one month after the toddler dose (13 months of age),GMC,3,18C,0.39,0.43,0.36,PCV7,pre-boost child,3+1 child,52
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,3,1.55,1.72,1.41,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,19F,2.86,3.24,2.53,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,18C,1.94,2.14,1.76,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,6B,1.49,1.75,1.27,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,14,4.61,5.23,4.07,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,23F,1.26,1.43,1.11,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,23F,1.44,1.65,1.25,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,5,1.31,1.46,1.17,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,9V,1.65,1.8,1.51,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,3,0.05,0.06,0.04,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,7F,2.59,2.85,2.36,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,1,0.03,0.03,0.02,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,6B,0.98,1.14,0.84,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,18C,2.25,2.49,2.04,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,19F,1.73,1.92,1.56,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,7F,0.04,0.05,0.04,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,6A,0.23,0.26,0.2,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,4,2.99,3.33,2.68,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,19A,0.64,0.71,0.58,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,9V,1.96,2.17,1.77,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,6A,1.33,1.49,1.18,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,14,4.14,4.66,3.68,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,1,1.83,2.04,1.64,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,4,2.18,2.4,1.98,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,5,0.2,0.23,0.18,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),GMC,3,19A,3.26,3.59,2.97,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,2,50.21,64.02,39.39,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,6B,1160.76,1462.19,921.46,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,2,50.21,64.02,39.39,PCV13,1m post primary child,3+1 child,0
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,14,3345.19,4524.5,2473.27,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,6B,1160.76,1462.19,921.46,PCV7,1m post primary child,3+1 child,0
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,6B,744.43,995.11,556.91,PCV13,1m post primary child,3+1 child,0
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,14,3345.19,4524.5,2473.27,PCV7,1m post primary child,3+1 child,0
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,6B,744.43,995.11,556.91,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,4,1860.79,2248.41,1540,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,4,1573.29,1929.21,1283.03,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,9V,5379.51,7353.34,3935.51,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,19F,165.69,223.23,122.98,PCV7,1m post primary child,3+1 child,0
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,9V,5379.51,7353.34,3935.51,PCV7,1m post primary child,3+1 child,0
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,23F,1070.83,1457.78,786.59,PCV7,1m post primary child,3+1 child,0
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,9V,4937.84,6745.14,3614.78,PCV13,1m post primary child,3+1 child,0
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,2,4.15,4.32,3.99,PCV7,1m post primary child,3+1 child,0
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,4,1573.29,1929.21,1283.03,PCV13,1m post primary child,3+1 child,0
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,23F,1089.92,1493.86,795.2,PCV13,1m post primary child,3+1 child,0
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,23F,1089.92,1493.86,795.2,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,9V,4937.84,6745.14,3614.78,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,14,2139.65,2915.79,1570.1,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,18C,1780.26,2292.59,1382.42,PCV7,1m post primary child,3+1 child,0
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,14,2139.65,2915.79,1570.1,PCV13,1m post primary child,3+1 child,0
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,23F,1070.83,1457.78,786.59,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,2,4.15,4.32,3.99,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,19F,165.69,223.23,122.98,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,18C,1509.65,1832.56,1243.64,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,19F,150.12,192.81,116.89,PCV13,1m post primary child,3+1 child,0
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,19F,150.12,192.81,116.89,PCV13,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,18C,1780.26,2292.59,1382.42,PCV7,1m post primary child,3+1 child,28
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,4,1860.79,2248.41,1540,PCV7,1m post primary child,3+1 child,0
NCT00366340,Wyeth is now a wholly owned subsidiary of Pfizer,Phase 3,"Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Europe","[""Child""]",One month after 3-dose infant series (5 months of age),OPA,3,18C,1509.65,1832.56,1243.64,PCV13,1m post primary child,3+1 child,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,14,1963.3,2673.4,1441.9,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,22F,982.1,1501,642.6,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,5,81.5,130,51.1,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,3,13.9,18.9,10.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,22F,1124.7,1682.9,751.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,6A,1673.9,2454.5,1141.5,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,19A,845.5,1100.6,649.5,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,9V,628.9,890.4,444.3,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,19A,1256.1,1535,1027.9,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,1,36,55.9,23.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,6B,1343.6,1817.3,993.3,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,3,32.8,45.2,23.8,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,19F,349.1,514.5,236.9,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,4,1060,1411.3,796.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,6A,1782.7,2532.1,1255.1,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,7F,877.7,1127.5,683.3,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,7F,1248.4,1631.4,955.3,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,18C,779.3,1041.8,582.9,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,19F,880.8,1168.6,663.9,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,1,43.4,65.5,28.8,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,9V,1134.8,1530.5,841.4,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,14,1762.9,2471.7,1257.3,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,23F,574.3,897.2,367.6,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,6B,1330.3,1940.8,911.8,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,18C,1125.6,1502.1,843.5,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,23F,755.6,1094.4,521.6,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,4,803.6,1074.2,601.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 30,OPA,2,5,117.3,164.9,83.5,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,9V,1555.6,2447.6,988.7,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,3,27.8,46.5,16.6,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,18C,1563.7,2850.3,857.8,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,7F,3830.5,5527.2,2654.6,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,1,100.7,200.9,50.5,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,22F,116.4,246.8,54.9,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,5,143.9,266.3,77.7,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,22F,30.9,57.5,16.6,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,18C,1890.8,2722.1,1313.3,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,6A,3945.3,6762.2,2301.9,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,9V,1606.5,2424.6,1064.5,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,14,1586.4,2791.3,901.6,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,5,350.5,636.1,193.2,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,7F,2064,3309,1287.4,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,14,2417,3774.1,1547.8,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,19A,2102.3,2819.5,1567.6,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,4,1051,1587,696,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,19A,1819.8,2547,1300.2,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,3,52.8,86.5,32.2,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,19F,1039.4,1672.2,646,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,23F,779.8,1467.8,414.3,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,23F,1245.8,2362.5,656.9,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,19F,640.4,1084.9,378.1,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,4,1075.7,1723.5,671.4,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,6B,2154.2,3501.3,1325.4,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,1,54.7,108.5,27.5,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,6A,4024.1,6174.1,2622.8,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 8,OPA,1,6B,1259.7,2243.5,707.3,PCV13+PPV23,2m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,2,6A,1843.2,3057.8,1111,PCV13+PPV23,3m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,2,1,39.7,77.4,20.4,PCV13+PPV23,3m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,2,23F,653.8,1353.4,315.8,PCV13+PPV23,3m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,1,3,9.2,13.7,6.2,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,1,6B,1125.1,1835.6,689.7,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,1,6A,1152.9,2029.3,655,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,2,18C,914.2,1406.2,594.3,PCV13+PPV23,3m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,2,19A,1024.3,1400.1,749.4,PCV13+PPV23,3m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,1,19A,806.3,1205.6,539.3,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,1,4,788.4,1161.1,535.3,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,1,14,1373.9,2146.1,879.5,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,1,7F,770.7,1189.2,499.5,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,2,22F,1228.3,2057.4,733.3,PCV13+PPV23,3m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,1,1,18.9,33.3,10.7,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,2,4,737.1,1202.1,451.9,PCV13+PPV23,3m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,1,19F,228.9,415.5,126.1,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,2,14,1458.2,2240.1,949.2,PCV13+PPV23,3m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,2,7F,1204.9,1744.8,832.1,PCV13+PPV23,3m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,2,3,19.6,32.1,12,PCV13+PPV23,3m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,1,5,65.6,118.8,36.2,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,1,23F,366.6,685.9,195.9,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,1,18C,691.1,1246.7,383.1,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,2,19F,563.7,923.7,344,PCV13+PPV23,3m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,2,6B,1157,2094.7,639,PCV13+PPV23,3m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,2,5,114.4,223.4,58.5,PCV13+PPV23,3m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,1,22F,45.2,86.7,23.5,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,1,9V,806.5,1298.7,500.9,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 26,OPA,2,9V,698.2,1113.8,437.7,PCV13+PPV23,3m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,2,22F,1766.3,2394.1,1303.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,1,22F,39,53.7,28.3,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,1,3,1189.9,1575.6,898.6,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,2,3,10413,13257.4,8178.9,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,1,14,1945,2405.1,1572.9,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,2,18C,2101.9,2550,1732.6,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,1,9V,1017.6,1309.4,790.8,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,1,23F,716.9,986.3,521.1,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,2,5,198.6,271,145.6,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,2,9V,1472.3,1820.2,1190.9,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,1,4,780,967.1,629.1,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,1,3,17.5,22.5,13.5,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,1,19A,1425.9,1745.8,1164.7,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,2,4,1079.3,1315.2,885.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,1,19F,627.2,802.2,490.5,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,2,19F,1051,1281.3,862.1,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,2,23F,1155.6,1539.9,867.2,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,1,5,148.4,204.1,107.9,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,2,7F,2250.8,2681.5,1889.3,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,1,1,57.1,79.3,41.1,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,2,1,81.7,110.7,60.4,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,1,18C,1587.1,2000.5,1259.1,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,2,19A,1785.8,2117.6,1506.1,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,2,14,2106.8,2627,1689.6,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,1,7F,1751.8,2157.6,1422.4,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,2,6B,1956.9,2431,1575.3,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,1,6B,1148.1,1482.6,889,PCV13+PPV23,3m post dose 1 adult,2 dose adult,0
NCT02225587,Merck Sharp & Dohme LLC,Phase 3,,"[""Adult"",""Older Adult""]",Week 12,OPA,2,3,43.4,55.9,33.7,PCV13+PPV23,1m post dose 2 adult,2 dose adult,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,23F,3.5,4.7,2.6,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,19F,10.93,13.38,8.92,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,5,0.77,0.92,0.64,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,7F,4.32,5.13,3.63,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,18C,3.05,3.82,2.43,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,6B,3.68,5.06,2.68,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,9V,1.57,1.97,1.25,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,1,2.47,3.38,1.81,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,14,7.4,10.2,5.37,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,4,2.59,3.22,2.08,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,18C,3.52,4.13,3,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,4,3.41,3.96,2.93,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,14,8.62,10.57,7.02,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,19F,7.59,11.29,5.1,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,7F,3.57,4.28,2.97,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,5,0.77,0.9,0.65,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,6B,4.28,5.27,3.48,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,9V,2.03,2.38,1.73,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,23F,2.76,3.44,2.22,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT02097472,PATH,"Phase 1, Phase 2",Africa,"[""Child"",""Adult""]",12 weeks (Cohort 1) and 4 weeks (Cohort 2) post-vaccination 1,GMC,1,1,3.09,3.83,2.5,PCV10 (Synflorix),1m post boost child,3+1 child,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,19A,12.21,13.76,10.83,PCV13,1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,23F,4.95,5.73,4.28,PCV10 (Pneumosil),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,6B,15.54,17.6,13.71,PCV13,1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,1,2.9,3.28,2.57,PCV10 (Synflorix),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,14,9.17,10.45,8.06,PCV13,1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,5,2.04,2.24,1.86,PCV13,1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,14,8.28,9.82,6.97,PCV10 (Pneumosil),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,9V,2.45,2.72,2.21,PCV10 (Synflorix),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,1,8.45,9.48,7.54,PCV10 (Pneumosil),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,19F,17.31,20.2,14.83,PCV10 (Synflorix),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,7F,6.31,6.93,5.75,PCV13,1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,6B,4.96,5.53,4.44,PCV10 (Synflorix),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,5,1.54,1.73,1.38,PCV10 (Pneumosil),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,6B,12.46,14.01,11.07,PCV10 (Pneumosil),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,7F,6.66,7.44,5.96,PCV10 (Pneumosil),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,6A,10.95,12.54,9.57,PCV13,1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,1,5.87,6.56,5.26,PCV13,1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,9V,3.87,4.32,3.47,PCV13,1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,6A,9.56,11.05,8.26,PCV10 (Pneumosil),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,23F,4.97,5.69,4.34,PCV13,1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,19F,14.99,16.96,13.25,PCV13,1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,19A,8.82,10.15,7.65,PCV10 (Pneumosil),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,19F,11.11,12.73,9.7,PCV10 (Pneumosil),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,9V,3.46,3.88,3.08,PCV10 (Pneumosil),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,14,5.02,5.97,4.22,PCV10 (Synflorix),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,5,0.8,0.88,0.72,PCV10 (Synflorix),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,19A,2.39,2.89,1.97,PCV10 (Synflorix),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,7F,3.15,3.45,2.87,PCV10 (Synflorix),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,6A,0.6,0.71,0.5,PCV10 (Synflorix),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,3,23F,2.16,2.44,1.92,PCV10 (Synflorix),1m post boost child,2+1 child,68
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,7F,1688.3,2456.74,1160.23,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,1,5.19,6.3,4.27,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,6A,42.59,68.55,26.46,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,6B,40.08,63.72,25.2,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,9V,27.95,44.67,17.48,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,5,16.03,23.45,10.95,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,19F,57.66,98.52,33.74,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,5,12.53,17.37,9.03,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,19F,12.27,20.5,7.34,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,6B,32.27,52.68,19.77,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,5,12.01,17.43,8.28,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,19F,24.09,41.77,13.9,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,6A,40.66,74,22.34,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,23F,81.42,150.4,44.08,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,1,5.57,6.8,4.56,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,7F,1725.63,2467.79,1206.66,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,1,5.45,6.49,4.57,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,23F,65.62,112.74,38.19,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,23F,41.99,75.68,23.29,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,14,62.77,116.08,33.95,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,19A,12.88,20.12,8.25,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,14,17.67,30.29,10.31,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,19A,13.43,23.11,7.8,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,14,60.53,112.55,32.55,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,19A,28.2,46.89,16.96,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,6B,121.6,189.36,78.09,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,9V,27.6,48.21,15.8,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,7F,1756.8,2499.24,1234.91,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,6A,6.41,9.15,4.49,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,0,9V,48.64,81.36,29.08,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,7F,0.72,0.8,0.64,PCV13,pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,1,0.36,0.41,0.33,PCV10 (Pneumosil),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,5,0.16,0.17,0.14,PCV10 (Synflorix),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,9V,0.29,0.32,0.26,PCV10 (Synflorix),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,19A,0.53,0.62,0.46,PCV13,pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,6A,0.62,0.7,0.55,PCV10 (Pneumosil),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,9V,0.28,0.31,0.25,PCV13,pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,19F,1.25,1.4,1.11,PCV10 (Synflorix),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,23F,0.32,0.37,0.27,PCV10 (Pneumosil),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,19F,0.83,0.94,0.73,PCV10 (Pneumosil),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,1,0.16,0.18,0.15,PCV10 (Synflorix),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,19A,0.49,0.56,0.42,PCV10 (Pneumosil),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,5,0.24,0.27,0.22,PCV13,pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,1,0.37,0.41,0.33,PCV13,pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,6B,0.56,0.62,0.5,PCV10 (Synflorix),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,14,1.16,1.35,1,PCV13,pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,19A,0.4,0.45,0.35,PCV10 (Synflorix),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,23F,0.17,0.2,0.15,PCV13,pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,9V,0.25,0.28,0.23,PCV10 (Pneumosil),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,6B,0.45,0.5,0.39,PCV13,pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,7F,0.6,0.68,0.53,PCV10 (Pneumosil),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,14,0.71,0.83,0.6,PCV10 (Pneumosil),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,7F,0.43,0.48,0.39,PCV10 (Synflorix),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,23F,0.16,0.19,0.15,PCV10 (Synflorix),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,6B,0.97,1.08,0.87,PCV10 (Pneumosil),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,19F,0.72,0.83,0.63,PCV13,pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,6A,0.22,0.25,0.19,PCV10 (Synflorix),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,14,0.48,0.56,0.41,PCV10 (Synflorix),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,6A,0.5,0.56,0.45,PCV13,pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",Prior to the booster dose at approximately 9 to 16 months of age,GMC,2,5,0.17,0.18,0.15,PCV10 (Pneumosil),pre-boost child,2+1 child,64
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,5,703.15,889.24,556.01,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,23F,1427.66,1835.05,1110.72,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,5,885.98,1185.37,662.2,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,9V,845.47,1132.13,631.39,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,6B,3931.21,5203.89,2969.79,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,19F,2541.4,3874.49,1666.99,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,7F,8288.88,10168.3,6756.83,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,23F,5687.6,8312.54,3891.57,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,1,631.29,851.59,467.98,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,19A,305.46,524.57,177.87,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,7F,4401.18,5390.5,3593.44,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,6B,1294.61,1803.11,929.52,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,14,2622.36,3725.47,1845.88,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,19A,3679.06,4634.19,2920.79,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,19F,2094.57,3109.94,1410.71,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,19A,1620.76,2188.13,1200.51,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,7F,7053.37,8425.18,5904.91,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,1,282.35,418.6,190.44,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,6A,6464.88,8162.19,5120.52,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,23F,2998.53,3955.89,2272.86,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,14,3131.96,4367.91,2245.73,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,19F,1384.38,2044.98,937.18,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,9V,1408.68,1816.64,1092.33,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,5,484.66,649.38,361.73,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,6B,6012.88,8752.29,4130.89,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,9V,2464.43,3102.85,1957.36,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,6A,53.86,115.56,25.1,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,1,429.13,592.14,310.99,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,6A,3651.54,5141.16,2593.53,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks post booster dose,GMC,0,14,1381.52,2160.74,883.3,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,14,669.79,1168.5,383.93,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,6A,1524.31,2179.09,1066.28,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,9V,331.79,455.89,241.48,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,19F,690.36,1033.61,461.1,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,7F,3069.95,3868.91,2435.98,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,19F,381.46,540.4,269.27,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,6B,920.43,1477.61,573.35,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,23F,748.96,1223.84,458.35,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,6A,400.49,672.79,238.4,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,6A,5.35,7.08,4.04,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,1,99.67,138.3,71.83,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,14,489.56,1069.94,224,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,5,182.18,246.7,134.53,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,7F,1096.84,1408.93,853.88,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,6B,166.74,313.43,88.71,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,5,85.09,122.75,58.98,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,19F,647.79,911.24,460.5,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,6B,923.86,1447.73,589.56,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,23F,806.12,1112.39,584.18,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,9V,134.5,207.1,87.35,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,19A,69.15,101.85,46.95,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,5,291.98,384.18,221.91,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,9V,58.24,88.58,38.29,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,19A,324.64,515.65,204.39,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,7F,2069.84,2639.98,1622.83,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,1,26.7,40.22,17.72,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,19A,22.4,37.83,13.27,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,23F,180.97,308.44,106.19,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,14,577.98,888.33,376.06,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,0,1,98.63,137.78,70.61,,,,0
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,5,1.19,1.28,1.1,PCV10 (Pneumosil),1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,19A,0.65,0.73,0.57,PCV10 (Synflorix),1m post boost child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,5,0.87,0.96,0.79,PCV10 (Synflorix),1m post boost child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,19F,8.86,10.17,7.71,PCV10 (Synflorix),1m post boost child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,19A,4.38,5.15,3.73,PCV13,1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,14,4.03,4.64,3.5,PCV10 (Pneumosil),1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,9V,2.56,2.88,2.28,PCV13,1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,1,3.4,3.74,3.1,PCV13,1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,23F,1.64,1.93,1.39,PCV13,1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,14,3.27,3.96,2.7,PCV13,1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,6A,2.62,3.08,2.24,PCV13,1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,19F,9.06,10.3,7.97,PCV13,1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,23F,2.21,2.56,1.92,PCV10 (Pneumosil),1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,19A,1.75,1.96,1.57,PCV10 (Pneumosil),1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,7F,4.67,5.2,4.19,PCV13,1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,6B,1.82,2.23,1.48,PCV10 (Pneumosil),1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,9V,1.93,2.16,1.74,PCV10 (Pneumosil),1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,19F,5.45,6.01,4.94,PCV10 (Pneumosil),1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,1,3.63,3.98,3.32,PCV10 (Pneumosil),1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,6B,0.91,1.1,0.75,PCV10 (Synflorix),1m post boost child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,6B,1.75,2.07,1.49,PCV13,1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,6A,0.14,0.16,0.13,PCV10 (Synflorix),1m post boost child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,23F,0.57,0.68,0.48,PCV10 (Synflorix),1m post boost child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,9V,1.31,1.46,1.17,PCV10 (Synflorix),1m post boost child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,14,2.58,3.04,2.18,PCV10 (Synflorix),1m post boost child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,7F,3.46,3.88,3.09,PCV10 (Pneumosil),1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,6A,1.19,1.41,1,PCV10 (Pneumosil),1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,5,1.81,2.01,1.62,PCV13,1m post primary child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,1,1.36,1.51,1.23,PCV10 (Synflorix),1m post boost child,2+1 child,18
NCT03896477,PATH,Phase 3,Africa,"[""Child""]",4 weeks after completion of primary vaccinations (at age 18 weeks),GMC,2,7F,1.73,1.92,1.55,PCV10 (Synflorix),1m post boost child,2+1 child,18
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,14,2.03,2.24,1.83,PCV13,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,23F,0.37,0.4,0.33,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,22F,0.05,0.05,0.04,PCV13,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,18C,0.28,0.3,0.25,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,4,0.26,0.28,0.24,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,6B,0.61,0.67,0.55,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,5,0.86,0.92,0.8,PCV13,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,14,1.34,1.48,1.22,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,19F,0.57,0.63,0.52,PCV13,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,1,0.46,0.5,0.43,PCV13,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,9V,0.48,0.52,0.44,PCV13,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,6A,0.58,0.64,0.54,PCV13,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,6B,0.56,0.62,0.51,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,4,0.26,0.27,0.24,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,9V,0.41,0.44,0.38,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,6B,0.5,0.55,0.46,PCV13,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,7F,0.77,0.83,0.72,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,7F,0.81,0.88,0.76,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,22F,1.3,1.4,1.2,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,6A,0.33,0.37,0.3,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,19A,0.4,0.44,0.36,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,19A,0.41,0.45,0.37,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,19A,0.5,0.55,0.45,PCV13,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,5,0.74,0.8,0.69,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,3,0.26,0.29,0.24,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,7F,1.05,1.12,0.98,PCV13,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,18C,0.41,0.44,0.38,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,3,0.12,0.14,0.11,PCV13,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,1,0.35,0.38,0.33,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,23F,0.29,0.32,0.26,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,4,0.27,0.29,0.25,PCV13,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,14,1.24,1.37,1.12,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,19F,0.43,0.46,0.39,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,9V,0.4,0.44,0.37,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,19F,0.47,0.52,0.43,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,18C,0.34,0.37,0.32,PCV13,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,3,0.25,0.27,0.23,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,1,0.32,0.34,0.29,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,22F,1.23,1.32,1.14,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,23F,0.32,0.36,0.28,PCV13,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,5,0.74,0.79,0.68,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",Before Vaccination 4 (Month 10 to 13),IgG,3,6A,0.38,0.41,0.35,PCV15,pre-boost child,3+1 child,60
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,4,1.26,1.38,1.14,PCV13,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,5,1.45,1.59,1.32,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,6A,1.42,1.59,1.27,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,7F,2.43,2.62,2.26,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,19F,2.57,2.78,2.38,PCV13,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,19A,1.63,1.76,1.52,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,3,1.02,1.11,0.93,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,14,4.78,5.34,4.27,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,9V,1.4,1.52,1.28,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,6A,1.48,1.63,1.34,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,4,1.3,1.4,1.21,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,7F,2.42,2.62,2.23,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,23F,1.25,1.4,1.11,PCV13,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,9V,1.59,1.76,1.44,PCV13,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,1,1.65,1.82,1.5,PCV13,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,3,0.53,0.58,0.48,PCV13,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,5,1.75,1.94,1.58,PCV13,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,6B,1.71,1.96,1.49,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,5,1.37,1.5,1.25,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,23F,1.22,1.35,1.1,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,22F,4.18,4.63,3.76,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,23F,1.47,1.63,1.32,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,3,1.04,1.12,0.97,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,19A,1.99,2.18,1.83,PCV13,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,7F,2.98,3.26,2.72,PCV13,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,22F,4.8,5.24,4.4,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,18C,1.65,1.79,1.52,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,1,1.19,1.27,1.1,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,19F,2.26,2.43,2.1,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,14,5.79,6.55,5.11,PCV13,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,9V,1.7,1.86,1.56,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,4,1.27,1.37,1.17,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,6B,1.95,2.28,1.68,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,18C,1.24,1.35,1.15,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,18C,1.67,1.82,1.52,PCV13,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,1,1.37,1.49,1.26,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,6A,2.62,2.92,2.35,PCV13,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,14,5.08,5.58,4.63,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,6B,1.89,2.18,1.64,PCV13,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,19F,2.33,2.53,2.15,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,22F,0.05,0.06,0.05,PCV13,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post Vaccination 3 (Month 5),IgG,3,19A,1.64,1.78,1.51,PCV15,1m post primary child,3+1 child,28
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,23F,3.38,3.78,3.02,PCV13,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,18C,2.75,3.05,2.47,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,3,1.16,1.26,1.06,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,5,3.43,3.8,3.09,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,14,7.29,8.14,6.54,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,7F,4.47,4.91,4.07,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,3,1.12,1.22,1.03,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,19A,6.53,7.18,5.93,PCV13,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,6A,4.97,5.51,4.49,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,9V,3.53,3.89,3.2,PCV13,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,4,1.88,2.1,1.69,PCV13,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,7F,6.29,6.91,5.73,PCV13,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,9V,2.43,2.69,2.2,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,6A,4.6,5.04,4.21,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,23F,2.52,2.83,2.25,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,19F,5.29,5.82,4.81,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,14,8.28,9.19,7.47,PCV13,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,3,0.78,0.85,0.71,PCV13,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,6B,6.91,7.63,6.25,PCV13,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,19A,5.8,6.31,5.33,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,6A,6.94,7.69,6.27,PCV13,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,19F,4.94,5.39,4.53,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,14,7.01,7.8,6.3,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,19F,5.47,6.01,4.97,PCV13,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,22F,7.54,8.23,6.91,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,4,1.53,1.7,1.37,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,1,2.47,2.72,2.24,PCV13,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,1,1.75,1.92,1.6,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,5,3.24,3.57,2.94,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,7F,4.25,4.66,3.87,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,23F,3.12,3.44,2.82,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,18C,2.94,3.26,2.65,PCV13,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,6B,7.38,8.15,6.68,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,22F,0.06,0.06,0.05,PCV13,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,1,2,2.19,1.84,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,19A,5.35,5.87,4.89,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,9V,2.71,2.96,2.47,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,6B,5.74,6.28,5.24,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,4,1.66,1.85,1.49,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,22F,8.6,9.42,7.85,PCV15,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,5,4.72,5.21,4.27,PCV13,1m post boost child,3+1 child,64
NCT02987972,Merck Sharp & Dohme LLC,Phase 2,"North America,North America,North America,North America,North America,North America,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,North America,Europe,North America,North America,Asia,North America,North America,Europe,North America,North America,Europe,North America,Asia,Europe,North America,Europe,North America,Europe,North America,Europe,North America,North America,North America,North America,Europe,North America,Asia,North America,North America,Europe,North America,North America,North America,Europe","[""Child""]",1 month post vaccination 4 (Month 11-14),IgG,4,18C,3.15,3.45,2.88,PCV15,1m post boost child,3+1 child,64
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,22F,7257.5,9978.3,5278.5,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,19A,14067.7,19843.9,9972.8,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,18C,5685.1,9707.6,3329.4,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,14,6597.6,9248,4706.8,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,6B,31560.4,41272.1,24134.1,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,7F,19411.5,24796.5,15195.9,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,6B,18531,31148.1,11024.7,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,9V,4561.8,6421.4,3240.7,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,23F,17190.9,24492.4,12066,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,19F,4931.8,7179.7,3387.8,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,4,7015.5,12322.6,3994,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,22F,1013.2,2150.1,477.4,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,9V,3941.7,5841.7,2659.6,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,1,504,997,254.8,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,19F,3313.3,5383.1,2039.4,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,1,484,715.4,327.5,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,6A,20277.1,35021.7,11740.2,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,5,1198.2,2250,638.1,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,6A,27305.7,37661.2,19797.6,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,7F,16928.1,25799,11107.4,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,18C,9684.6,14120.7,6642.1,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,23F,19197.1,35061.1,10511.1,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,14,8112.2,13632.8,4827.2,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,3,234.3,412.6,133,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,5,1383.9,2000.9,957.1,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,19A,9224.9,16967.1,5015.5,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,4,4670.8,7355.6,2965.9,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,OPA,1,3,264.8,362.4,193.4,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,18C,6.11,8.35,4.47,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,23F,6.88,11.83,4.01,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,14,16.03,22.9,11.23,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,5,6.56,10.52,4.09,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,7F,4.65,7.06,3.06,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,6B,22.94,38.71,13.6,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,3,1.09,1.38,0.87,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,4,2.9,4.2,2,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,1,2.76,3.91,1.95,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,4,1.58,2.1,1.18,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,14,20.53,34.03,12.39,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,19A,21.65,32.44,14.45,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,18C,4.2,6.62,2.66,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,5,4.44,6.17,3.19,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,19A,19.86,26.7,14.77,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,3,1.07,1.65,0.7,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,6A,15.97,28.91,8.82,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,7F,5.81,7.64,4.42,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,9V,4.46,5.78,3.44,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,9V,5.36,8.33,3.45,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,22F,7.3,9.36,5.68,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,19F,12.8,18.01,9.1,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,6A,23.29,31.52,17.22,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,19F,13.88,19.35,9.96,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,22F,0.49,0.73,0.33,PCV13,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,6B,38.38,51.64,28.53,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,1,2.12,2.75,1.63,PCV15,1m post boost child,,0
NCT03731182,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,South America,Europe,South America,South America,North America,North America,North America,North America,Europe,North America,North America,South America,North America,South America,North America,North America,Europe","[""Child""]",Day 30,IgG,1,23F,5.38,7.46,3.88,PCV15,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,4,4.27,5.11,3.57,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,14,20.38,25.35,16.39,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,5,2.94,3.54,2.44,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,22F,0.24,0.29,0.2,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,19A,14.2,17.07,11.81,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,4,2.59,3,2.23,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,14,18.29,23.17,14.43,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,6B,11.44,14.43,9.07,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,3,1.05,1.19,0.93,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,19F,8.61,10.18,7.28,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,3,0.84,0.97,0.73,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,7F,5,5.83,4.29,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,6B,6.92,8.79,5.45,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,19A,14.78,17.54,12.45,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,5,2.78,3.37,2.3,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,18C,5.18,6.2,4.32,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,1,3.26,3.77,2.82,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,23F,6.71,8.31,5.42,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,6A,7.98,10.11,6.3,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,6A,7.56,9.45,6.06,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,1,2.17,2.48,1.89,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,22F,9.28,11.09,7.76,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,19F,9.76,11.85,8.03,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,9V,4.15,4.85,3.56,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,23F,6.35,7.85,5.14,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,9V,4.78,5.66,4.03,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,18C,5.15,6.18,4.29,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,IgG,1,7F,4.84,5.71,4.1,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,23F,4.83,5.88,3.96,PCV13+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,18C,3.75,4.43,3.18,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,14,19.89,24.72,16,PCV13+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,14,18.88,23.09,15.43,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,19A,11.23,13.31,9.48,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,3,1.08,1.24,0.94,PCV13+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,22F,10.32,12.29,8.67,PCV13+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,4,2.36,2.69,2.08,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,9V,3.69,4.25,3.2,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,6A,4.91,6.11,3.94,PCV13+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,6B,4.96,6.22,3.96,PCV13+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,18C,4.11,4.85,3.48,PCV13+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,1,3.33,3.75,2.95,PCV13+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,4,3.61,4.23,3.09,PCV13+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,6B,7.12,8.81,5.75,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,1,2.58,2.88,2.31,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,5,3.01,3.52,2.58,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,19F,7.98,9.33,6.83,PCV13+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,19A,12.19,14.32,10.38,PCV13+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,5,3.24,3.82,2.75,PCV13+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,7F,4.1,4.72,3.55,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,19F,8.56,10.08,7.26,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,9V,4.52,5.24,3.89,PCV13+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,3,1.1,1.24,0.97,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,23F,4.4,5.34,3.63,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,6A,4.67,5.84,3.74,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,7F,4.27,4.92,3.71,PCV13+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,IgG,2,22F,8.18,9.42,7.1,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,5,847.6,1070.4,671.1,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,6A,11915.4,13973,10160.9,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,3,330,383,284.4,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,22F,10791.3,12716.9,9157.2,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,7F,18519.3,21420.8,16010.9,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,5,642.1,839.9,490.9,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,23F,11693.1,14417.1,9483.8,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,6A,14274.6,16960.4,12014.1,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,19A,8690.2,10229.8,7382.3,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,1,398.3,506.1,313.5,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,18C,4556.2,5471.5,3794.1,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,18C,3543,4299.5,2919.6,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,6B,15052.9,17814.2,12719.6,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,22F,503.1,766.8,330.1,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,3,301.5,355.7,255.5,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,19F,3277.6,3791.8,2833.1,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,6B,17636.5,21118.3,14728.7,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,23F,11933.8,14838.8,9597.5,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,9V,5879.7,7122.2,4853.9,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,4,9172.8,11096.1,7582.8,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,19F,3711.8,4335.2,3178,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,9V,4800,5484.4,4201,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,14,17920.8,21591.2,14874.4,PCV13,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,4,6078.3,7235.4,5106.1,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,7F,17574.4,20274,15234.2,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,19A,8176.4,9862.8,6778.3,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,14,18444.3,22297,15257.3,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Day 30,OPA,1,1,353.4,448.7,278.4,PCV15,1m post primary child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,14,17207.5,21037.9,14074.5,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,5,939.5,1197.3,737.3,PCV13+PPV23,1m post boost child,Not selected,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,4,5445.7,6358.8,4663.7,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,23F,10216.7,12329.8,8465.7,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,18C,3369,3990.9,2844,PCV13+PPV23,1m post boost child,Not selected,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,6B,12745.8,14921.6,10887.3,PCV13+PPV23,1m post boost child,Not selected,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,7F,17415.9,20098.5,15091.4,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,19F,3694.8,4248.9,3212.9,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,9V,5135.9,6094.3,4328.2,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,7F,19140.5,21835,16778.5,PCV13+PPV23,1m post boost child,Not selected,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,23F,10086,12206.2,8334,PCV13+PPV23,1m post boost child,Not selected,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,9V,6152.2,7251.4,5219.6,PCV13+PPV23,1m post boost child,Not selected,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,14,16461.2,19785.9,13695.1,PCV13+PPV23,1m post boost child,Not selected,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,1,326.4,399,267,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,22F,8756.1,10334.1,7419,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,6A,10208.7,11973.7,8703.8,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,18C,3635.1,4258.5,3103,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,19A,7613.7,9036.9,6414.6,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,6A,10699.8,12705.7,9010.5,PCV13+PPV23,1m post boost child,Not selected,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,5,985.6,1193.8,813.6,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,19A,8838,10287.6,7592.6,PCV13+PPV23,1m post boost child,Not selected,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,3,327.2,383.9,278.9,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,22F,6958,8148.5,5941.5,PCV13+PPV23,1m post boost child,Not selected,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,19F,3904.4,4507.1,3382.3,PCV13+PPV23,1m post boost child,Not selected,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,1,337,417.1,272.3,PCV13+PPV23,1m post boost child,Not selected,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,6B,13774.8,16271,11661.6,PCV15+PPV23,1m post boost child,,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,4,7526.8,8978.7,6309.7,PCV13+PPV23,1m post boost child,Not selected,0
NCT03921424,Merck Sharp & Dohme LLC,Phase 3,"Asia,Europe,Asia,Europe,Africa,Europe,Africa,Europe,Asia,Asia,Africa,Africa,Europe","[""Child""]",Week 12,OPA,2,3,384.8,444.6,333,PCV13+PPV23,1m post boost child,Not selected,0
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,7F,1.95,2.62,1.46,PCV15,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,4,1.27,1.68,0.96,PCV13,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,22F,0.05,0.07,0.03,PCV13,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,3,0.86,1.13,0.65,PCV15,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,22F,4.33,5.9,3.18,PCV15,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,14,4.38,6.03,3.18,PCV15,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,14,6.52,9.77,4.35,PCV13,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,19F,2.78,3.58,2.17,PCV13,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,5,1.48,2.1,1.04,PCV15,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,4,1.41,1.99,1.01,PCV15,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,1,1.15,1.52,0.88,PCV15,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,3,0.58,0.76,0.45,PCV13,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,6B,1.69,2.48,1.15,PCV15,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,1,1.61,2.09,1.25,PCV13,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,5,1.66,2.53,1.09,PCV13,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,19A,3,4.11,2.18,PCV13,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,6A,1.37,1.96,0.95,PCV15,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,9V,1.47,2,1.08,PCV15,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,9V,1.5,2.12,1.07,PCV13,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,7F,2.92,3.87,2.21,PCV13,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,19F,2.03,2.68,1.53,PCV15,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,18C,1.54,2.04,1.16,PCV13,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,6B,2.53,3.89,1.64,PCV13,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,23F,1.18,1.68,0.82,PCV13,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,23F,1.17,1.7,0.81,PCV15,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,6A,3.19,4.43,2.31,PCV13,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,19A,1.63,2.13,1.25,PCV15,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 3 (approximately 5 months after Vaccination 1),IgG,3,18C,1.46,1.96,1.08,PCV15,1m post primary child,3+1 child,24
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,23F,3.04,4.27,2.16,PCV13,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,19F,4.83,6.38,3.66,PCV13,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,14,7.15,9.61,5.33,PCV13,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,22F,0.08,0.11,0.07,PCV13,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,7F,4.01,5.4,2.98,PCV15,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,3,1.04,1.36,0.8,PCV15,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,18C,2.77,3.85,1.99,PCV13,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,18C,3.21,4.45,2.32,PCV15,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,1,1.96,2.5,1.54,PCV13,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,22F,9.83,12.92,7.47,PCV15,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,5,3.6,5.13,2.53,PCV13,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,19A,6.47,9.4,4.46,PCV13,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,6A,4.18,5.49,3.17,PCV15,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,4,1.61,2.15,1.21,PCV13,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,19F,4.48,5.73,3.51,PCV15,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,19A,4.96,6.39,3.85,PCV15,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,1,1.56,2.06,1.19,PCV15,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,6B,6.62,8.37,5.24,PCV15,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,3,0.79,1.06,0.6,PCV13,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,5,3.3,4.65,2.34,PCV15,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,9V,3.1,4.08,2.36,PCV15,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,7F,5.1,6.9,3.76,PCV13,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,23F,2.38,3.2,1.76,PCV15,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,9V,3.09,4.12,2.31,PCV13,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,4,1.55,2.16,1.11,PCV15,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,6B,6.75,10.28,4.43,PCV13,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,6A,6.38,8.68,4.69,PCV13,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",30 days after Vaccination 4 (11-14 months after Vaccination 1),IgG,4,14,5.4,7.49,3.89,PCV15,1m post boost child,3+1 child,64
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,9V,0.4,0.51,0.32,PCV15,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,6B,0.59,0.75,0.47,PCV15,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,14,2.22,2.84,1.73,PCV13,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,18C,0.35,0.45,0.28,PCV15,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,1,0.3,0.38,0.24,PCV15,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,1,0.47,0.59,0.38,PCV13,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,7F,0.57,0.73,0.44,PCV15,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,22F,1.24,1.58,0.98,PCV15,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,7F,0.95,1.21,0.74,PCV13,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,5,0.77,1.01,0.6,PCV15,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,4,0.24,0.31,0.19,PCV15,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,14,1.14,1.54,0.84,PCV15,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,4,0.31,0.38,0.24,PCV13,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,9V,0.46,0.62,0.35,PCV13,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,3,0.22,0.29,0.16,PCV15,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,6A,0.72,0.99,0.52,PCV13,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,22F,0.05,0.07,0.04,PCV13,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,3,0.13,0.17,0.1,PCV13,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,19F,0.69,0.9,0.52,PCV13,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,23F,0.37,0.52,0.26,PCV13,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,5,0.89,1.22,0.65,PCV13,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,19A,0.38,0.51,0.29,PCV15,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,19F,0.41,0.53,0.31,PCV15,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,19A,0.81,1.24,0.52,PCV13,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,23F,0.33,0.45,0.24,PCV15,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,18C,0.36,0.49,0.27,PCV13,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,6A,0.32,0.43,0.24,PCV15,pre-boost child,3+1 child,60
NCT03692871,Merck Sharp & Dohme LLC,Phase 3,"North America,Europe,Asia,South America,Australia & Oceania,Europe,North America,North America,Europe,North America,North America,North America,North America,Asia,Europe,North America,Asia,Asia,Asia,North America,Asia,North America,Europe,Australia & Oceania,North America,South America,North America,Asia,North America,Asia,Europe,North America,North America,Asia,Europe,Europe,North America,North America,Europe,North America,Europe,North America,North America,Asia,North America,Asia,Asia,Asia,Europe,North America,Europe,Asia,Asia,North America,Asia,North America,Europe,North America,Europe,Europe,South America,Asia,North America,Asia,Europe,Australia & Oceania,Asia,North America,Asia,North America,Asia,Europe,North America,Europe,Europe,North America","[""Child""]",Before Vaccination 4 (10-13 months after Vaccination 1),IgG,3,6B,0.61,0.87,0.43,PCV13,pre-boost child,3+1 child,60
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,1,1.99,2.21,1.78,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,19A,2.17,2.47,1.92,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,23F,1.33,1.57,1.14,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,9V,2.01,2.24,1.8,PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,6B,2.43,2.88,2.05,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,23F,1.32,1.59,1.09,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,4,1.4,1.57,1.24,PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,4,1.47,1.66,1.3,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,23F,1.46,1.69,1.25,PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,7F,2.61,2.94,2.33,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,3,0.56,0.63,0.49,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,22F,0.05,0.05,0.04,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,6B,2.03,2.49,1.66,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,3,1.01,1.12,0.91,PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,6B,2.26,2.73,1.87,PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,19A,2.25,2.6,1.95,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,5,2.16,2.49,1.87,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,6B,2.29,2.76,1.91,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,1,1.93,2.2,1.69,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,6A,2.05,2.38,1.76,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,19F,2.83,3.18,2.51,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,19F,2.21,2.46,2,PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,6A,1.82,2.09,1.59,PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,19F,2.9,3.23,2.61,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,3,0.54,0.61,0.47,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,6B,2.5,2.99,2.1,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,22F,0.05,0.06,0.04,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,5,1.99,2.34,1.69,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,14,6.18,7.31,5.22,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,3,0.64,0.73,0.56,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,7F,3.54,3.96,3.16,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,1,1.27,1.41,1.14,PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,19A,1.64,1.87,1.43,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,1,1.86,2.1,1.64,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,22F,5.94,6.88,5.13,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,19F,3.08,3.48,2.72,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,5,1.73,1.99,1.5,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,1,1.35,1.53,1.19,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,22F,3.63,4.52,2.91,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,7F,2.41,2.67,2.17,PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,19A,1.63,1.82,1.47,PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,4,1.39,1.57,1.22,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,5,2.15,2.52,1.83,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,14,9.32,11.67,7.45,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,9V,1.81,2.05,1.6,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,9V,1.47,1.67,1.28,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,9V,1.68,1.97,1.44,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,18C,1.51,1.72,1.34,PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,23F,1.72,1.99,1.49,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,7F,3.52,3.99,3.1,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,6A,3.22,3.67,2.83,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,6A,3.26,3.82,2.79,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,18C,2.08,2.38,1.81,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,18C,1.69,1.95,1.46,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,9V,1.69,1.94,1.48,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,18C,1.5,1.71,1.33,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,23F,1.22,1.45,1.02,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,14,5.5,6.31,4.79,PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,4,1.34,1.56,1.14,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,14,6.57,7.79,5.55,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,14,6.71,7.83,5.76,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,4,1.07,1.22,0.93,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,7F,3.36,3.77,2.99,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,3,0.67,0.76,0.6,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,18C,2.03,2.28,1.81,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,19F,2.32,2.62,2.06,PCV13+PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,6A,3.07,3.54,2.66,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,19A,2.46,2.74,2.21,PCV13,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,5,1.91,2.18,1.67,PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 3 (Month 5),IgG,3,22F,5.15,5.87,4.52,PCV15,1m post primary child,3+1 child,20
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,19A,4.95,5.73,4.27,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,9V,2.76,3.16,2.41,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,7F,5.69,6.56,4.93,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,14,7.87,9.16,6.77,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,5,2.9,3.35,2.5,PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,14,10.91,12.81,9.29,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,7F,3.43,3.91,3.02,PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,1,2.02,2.3,1.78,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,18C,2.76,3.15,2.42,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,9V,2.46,2.78,2.19,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,9V,2.89,3.26,2.56,PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,4,1.23,1.41,1.08,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,19A,4.66,5.24,4.15,PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,1,1.46,1.63,1.3,PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,23F,2.29,2.7,1.93,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,6A,5.17,6.03,4.43,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,9V,2.57,2.97,2.22,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,5,3.82,4.51,3.23,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,3,0.72,0.82,0.64,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,4,1.33,1.56,1.14,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,14,7.62,8.86,6.55,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,19F,4.88,5.51,4.33,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,6A,4.43,5.09,3.86,PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,4,1.35,1.57,1.17,PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,6A,6.42,7.42,5.56,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,19F,5.02,5.73,4.4,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,3,0.77,0.87,0.68,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,19A,5.52,6.25,4.88,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,3,0.68,0.77,0.61,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,14,6.57,7.55,5.73,PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,23F,2.72,3.18,2.33,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,9V,2.93,3.34,2.56,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,1,1.68,1.91,1.48,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,5,2.9,3.38,2.5,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,1,1.69,1.93,1.48,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,6B,6.64,7.69,5.73,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,7F,3.98,4.57,3.47,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,6B,6.62,7.62,5.75,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,19A,5.92,6.8,5.15,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,5,3.39,3.94,2.91,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,6B,7.58,8.68,6.61,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,6B,5.83,6.68,5.09,PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,23F,2.89,3.44,2.42,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,23F,2.11,2.46,1.81,PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,1,1.89,2.18,1.63,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,18C,3.88,4.45,3.38,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,7F,5.1,5.88,4.43,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,7F,5.06,5.92,4.33,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,19F,4.78,5.42,4.22,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,4,1.27,1.46,1.1,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,18C,3.7,4.29,3.2,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,5,3.66,4.2,3.18,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,19F,4.1,4.59,3.66,PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,3,0.89,0.99,0.79,PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,18C,2.57,2.99,2.21,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,19A,5.2,6.12,4.42,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,6A,7.16,8.3,6.17,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,19F,4.6,5.28,4,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,3,0.73,0.82,0.66,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,6A,7.16,8.15,6.3,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,6B,6.15,7.07,5.36,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,14,10.59,12.44,9.01,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,18C,2.65,3.01,2.34,PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,23F,2.22,2.56,1.92,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,4,1.51,1.76,1.3,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,3,0.72,0.82,0.64,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,6B,6.15,7.07,5.36,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,4,1.35,1.57,1.17,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,9V,2.89,3.26,2.56,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,18C,2.57,2.99,2.21,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,19A,5.92,6.8,5.15,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,6A,4.43,5.09,3.86,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,23F,2.89,3.44,2.42,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,19F,4.78,5.42,4.22,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,9V,2.93,3.34,2.56,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,23F,2.11,2.46,1.81,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,19A,4.66,5.24,4.15,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,6A,6.42,7.42,5.56,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,1,1.46,1.63,1.3,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,5,3.66,4.2,3.18,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,19F,4.1,4.59,3.66,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,7F,3.43,3.91,3.02,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,3,0.89,0.99,0.79,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,14,7.62,8.86,6.55,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,7F,5.1,5.88,4.43,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,4,1.51,1.76,1.3,PCV13,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,6B,5.83,6.68,5.09,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,14,6.57,7.55,5.73,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,5,2.9,3.35,2.5,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,18C,2.65,3.01,2.34,PCV13+PCV15,1m post boost child,3+1 child,56
NCT03620162,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,Europe Asia,North America,North America,Asia,North America,Asia,Asia,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America","[""Child""]",30 Days after Vaccination 4 (Months 11-14),IgG,4,1,2.02,2.3,1.78,PCV13,1m post boost child,3+1 child,56
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,3,0.71,0.75,0.67,PCV13,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,3,0.96,1.01,0.91,PCV15,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,14,5.61,6.04,5.21,PCV15,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,19A,4.1,4.33,3.88,PCV15,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,1,2.03,2.14,1.92,PCV13,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,6A,6.21,6.62,5.83,PCV13,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,6B,4.76,5.1,4.43,PCV15,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,23F,3.32,3.58,3.08,PCV13,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,1,1.35,1.42,1.27,PCV15,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,7F,4.85,5.16,4.56,PCV13,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,18C,3.08,3.29,2.88,PCV13,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,7F,3.42,3.64,3.22,PCV15,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,22F,7.52,7.98,7.09,PCV15,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,23F,2.04,2.18,1.91,PCV15,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,3,0.71,0.75,0.67,PCV13,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,4,1.6,1.71,1.51,PCV13,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,9V,2.4,2.55,2.27,PCV15,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,19F,3.55,3.75,3.37,PCV15,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,6A,3.7,3.97,3.46,PCV15,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,4,1.23,1.31,1.16,PCV15,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,18C,2.62,2.78,2.46,PCV15,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,22F,0.11,0.12,0.1,PCV13,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,14,6.95,7.43,6.51,PCV13,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,5,3.95,4.2,3.71,PCV13,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,19A,5.53,5.87,5.21,PCV13,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,6B,6.43,6.88,6.02,PCV13,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,19F,4.47,4.73,4.23,PCV13,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,9V,3.29,3.49,3.1,PCV13,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,5,2.49,2.64,2.34,PCV15,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 4 (Month 13 to Month 16),IgG,4,3,0.96,1.01,0.91,PCV15,1m post boost child,3+1 child,64
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,3,1.08,1.14,1.03,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,3,0.62,0.66,0.59,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,22F,4.91,5.26,4.58,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,4,1.35,1.43,1.28,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,22F,0.05,0.06,0.05,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,19F,2.01,2.11,1.91,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,18C,1.53,1.61,1.44,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,6B,1.6,1.76,1.45,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,19A,2.29,2.44,2.16,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,3,0.62,0.66,0.59,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,19F,2.72,2.86,2.59,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,9V,1.73,1.83,1.63,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,6A,1.55,1.66,1.44,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,7F,3.23,3.4,3.06,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,23F,1.47,1.59,1.36,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,7F,2.48,2.61,2.35,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,5,2.25,2.41,2.09,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,6B,1.97,2.16,1.8,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,23F,1.31,1.41,1.22,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,19A,1.63,1.73,1.54,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,1,1.89,2,1.79,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,14,6.8,7.33,6.3,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,5,1.63,1.74,1.52,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,3,1.08,1.14,1.03,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,6A,2.95,3.15,2.76,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,1,1.21,1.27,1.15,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,14,4.78,5.16,4.44,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,4,1.29,1.36,1.22,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,9V,1.89,2.01,1.77,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),IgG,3,18C,2,2.13,1.88,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,3,79.2,,,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,3,94.7,,,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,1,78.3,99.5,61.5,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,5,387.4,476.3,315,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,23F,3668.8,4385.6,3069.2,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,9V,1534.1,1802.8,1305.5,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,22F,9.1,10.4,7.9,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,6B,1932.5,2316.6,1612.1,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,19A,841.3,988.6,716,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,22F,1849.3,2128.2,1606.9,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,23F,2078.9,2428.9,1779.2,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,19A,1400.7,1627.4,1205.5,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,1,56.9,70.3,46.1,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,3,284.7,319.8,253.5,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,19F,703.9,806.6,614.2,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,9V,1217.3,1424.6,1040.2,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,18C,1330.2,1527.5,1158.3,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,5,510.8,627.2,415.9,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,6A,2072.1,2401.9,1787.5,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,3,210.6,235.7,188.2,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,4,1304.8,1494,1139.6,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,19F,850.6,971.9,744.5,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,6B,1963.7,2402.8,1604.9,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,4,1566.7,1776.4,1381.8,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,7F,4973.2,5781.8,4277.6,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,14,2400.7,2909.6,1980.8,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,14,1853.1,2272.5,1511.2,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,7F,7335.1,8703.5,6181.8,PCV13,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,18C,1171.2,1341.4,1022.7,PCV15,1m post primary child,3+1 child,28
NCT03893448,Merck Sharp & Dohme LLC,Phase 3,"North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,Asia,North America,Europe Asia,North America,North America,North America,North America,North America,North America,Asia,North America,North America,North America,Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,Europe Asia,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America,North America","[""Child""]",One month after Vaccination 3 (Month 7),OPA,3,6A,2743.4,3178.2,2368.1,PCV13,1m post primary child,3+1 child,28
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,3,1.37,1.58,1.19,PCV15,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,1,3.99,4.58,3.48,PCV13,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,6B,13.55,17.46,10.52,PCV15,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,6A,8.81,11.14,6.96,PCV13,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,23F,5.12,6.37,4.12,PCV13,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,22F,14.99,17.66,12.73,PCV15,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,1,3,3.46,2.6,PCV15,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,18C,7.16,8.52,6.03,PCV15,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,6B,10.51,13.78,8.01,PCV13,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,7F,4.03,4.7,3.46,PCV15,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,19A,14.9,18.16,12.23,PCV13,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,4,5.22,6.03,4.52,PCV13,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,14,9.21,11.92,7.11,PCV15,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,23F,5.36,6.5,4.41,PCV15,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,19F,8.95,10.76,7.45,PCV15,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,9V,3.6,4.24,3.06,PCV15,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,6A,9.03,11.53,7.07,PCV15,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,19A,10.99,13.26,9.12,PCV15,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,14,8.04,10.36,6.24,PCV13,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,3,1.03,1.21,0.88,PCV13,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,9V,4.35,5.2,3.65,PCV13,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,22F,0.31,0.38,0.24,PCV13,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,18C,4.46,5.3,3.76,PCV13,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,7F,4.63,5.46,3.92,PCV13,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,19F,12.28,14.97,10.07,PCV13,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,5,3.43,4.07,2.89,PCV15,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,4,2.53,2.96,2.17,PCV15,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post vaccination,IgG,1,5,4.24,5.2,3.46,PCV13,1m post dose 1 child,0+1 child,116
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,14,9.62,11.67,7.94,PCV15,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,14,13.07,16.42,10.4,PCV13,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,3,1.71,2.08,1.4,PCV13,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,19F,4.83,5.79,4.03,PCV13,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,22F,9.04,10.93,7.48,PCV15,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,1,3.66,4.5,2.98,PCV13,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,23F,2.79,3.69,2.1,PCV13,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,18C,3.5,4.45,2.75,PCV13,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,19A,4.59,5.33,3.95,PCV15,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,23F,2.62,3.39,2.02,PCV15,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,6A,2.23,2.91,1.71,PCV15,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,4,3.85,4.76,3.12,PCV13,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,6B,4.17,5.36,3.25,PCV13,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,6A,4.3,5.65,3.28,PCV13,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,19F,3.49,4.15,2.94,PCV15,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,4,2.21,2.68,1.82,PCV15,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,6B,3.03,3.82,2.41,PCV15,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,7F,5.16,6.23,4.27,PCV15,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,19A,5.81,6.85,4.92,PCV13,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,22F,0.14,0.19,0.1,PCV13,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,9V,2.61,3.26,2.09,PCV15,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,9V,3.59,4.51,2.86,PCV13,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,3,2.65,3.05,2.3,PCV15,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,7F,6.42,7.85,5.25,PCV13,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,1,2.47,2.92,2.09,PCV15,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,18C,3.45,4.24,2.8,PCV15,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,5,4.56,5.8,3.58,PCV13,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,3,5,3.82,4.63,3.14,PCV15,1m post boost child,2+1 child,52
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,19A,5.87,7.11,4.85,PCV13,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,3,1.68,2.2,1.29,PCV13,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,5,3.12,3.88,2.52,PCV13,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,4,3.46,4.5,2.67,PCV15,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,9V,2.89,3.78,2.21,PCV13,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,23F,2.18,3.07,1.54,PCV13,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,23F,2.85,4.07,1.99,PCV15,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,14,8.3,10.51,6.56,PCV13,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,22F,15.9,20.78,12.16,PCV15,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,19F,5.9,7.43,4.69,PCV15,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,6A,3.73,5.29,2.64,PCV13,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,18C,3.68,4.75,2.85,PCV13,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,6B,2.69,4.25,1.7,PCV15,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,4,4.89,6.36,3.76,PCV13,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,19F,5.92,7.11,4.93,PCV13,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,7F,5.42,6.82,4.3,PCV13,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,1,4.2,5.34,3.3,PCV13,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,5,3.39,4.34,2.65,PCV15,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,6A,2.05,3.23,1.3,PCV15,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,22F,0.12,0.16,0.09,PCV13,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,14,8.23,10.94,6.19,PCV15,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,3,2.96,3.58,2.44,PCV15,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,7F,4.8,6.34,3.63,PCV15,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,19A,6.74,8.6,5.29,PCV15,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,9V,2.48,3.11,1.97,PCV15,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,18C,5.09,6.52,3.98,PCV15,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,1,3.83,4.77,3.07,PCV15,1m post dose 2 child,0+2 child,96
NCT03885934,Merck Sharp & Dohme LLC,Phase 3,"Europe Asia,Europe,Europe,Europe Asia,Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Europe,Europe,Asia,Europe Asia,Europe,Asia,Europe,Europe,Europe,Europe,Europe,Europe,Europe,Asia,Asia","[""Child""]",30 days post last vaccination,IgG,2,6B,2.87,4.3,1.92,PCV13,1m post dose 2 child,0+2 child,96
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,23F,11.55,23.08,5.78,PCV15 (medium dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,9V,2.76,6.46,1.18,PCV15 (medium dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,3,0.71,1.15,0.44,PCV15 (high dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,14,9.96,23.41,4.24,PCV15 (high dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,6B,3.71,10.14,1.36,PCV15 (high dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,6A,8.42,19.98,3.55,PCV15 (medium dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,14,14.97,33.84,6.62,PCV15 (medium dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,5,3.08,6.74,1.41,PCV15 (medium dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,19A,4.62,8.16,2.61,PCV15 (high dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,18C,9.48,19.91,4.51,PCV15 (medium dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,1,3.47,6.61,1.83,PCV15 (medium dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,7F,5.12,11.17,2.35,PCV15 (medium dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,18C,8.91,18.04,4.4,PCV15 (high dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,7F,6.12,11.34,3.3,PCV15 (high dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,6A,4.78,11.47,1.99,PCV15 (high dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,6B,7.25,17.35,3.03,PCV15 (medium dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,19A,15.19,23.41,9.85,PCV15 (medium dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,4,1.47,2.86,0.76,PCV15 (high dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,9V,2.27,4.04,1.28,PCV15 (high dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,22F,2.93,4.78,1.8,PCV15 (medium dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,3,0.5,0.82,0.31,PCV15 (medium dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,19F,8.67,18.15,4.15,PCV15 (medium dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,23F,8.91,19.2,4.14,PCV15 (high dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,1,4.99,9.93,2.51,PCV15 (high dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,4,0.96,1.65,0.56,PCV15 (medium dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,19F,7.96,14.61,4.33,PCV15 (high dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,5,2.2,4.77,1.02,PCV15 (high dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after vaccination,IgG,1,22F,4.04,6.86,2.38,PCV15 (high dose),1m post dose 1 adult,1 dose adult,0
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,6A,1.52,2.16,1.07,PCV15 (high dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,19F,2.19,2.66,1.8,PCV13,1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,18C,1.22,1.51,0.99,PCV15 (high dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,23F,1.16,1.61,0.83,PCV15 (high dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,19F,1.81,2.28,1.44,PCV15 (medium dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,23F,1.08,1.62,0.72,PCV15 (medium dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,3,1.12,1.41,0.89,PCV15 (high dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,9V,1.48,1.97,1.1,PCV13,1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,6B,1.3,2.02,0.83,PCV15 (high dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,19A,1.63,2.21,1.2,PCV13,1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,23F,1.19,1.71,0.82,PCV13,1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,3,0.94,1.13,0.78,PCV15 (medium dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,5,1.29,1.74,0.96,PCV15 (medium dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,14,4.94,6.95,3.51,PCV13,1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,7F,2.97,3.93,2.24,PCV13,1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,19F,2.37,2.83,1.99,PCV15 (high dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,9V,1.68,2.29,1.24,PCV15 (medium dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,18C,1.54,2.07,1.14,PCV13,1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,14,4.58,5.67,3.7,PCV15 (high dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,1,1.63,2.07,1.28,PCV13,1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,6B,1.8,2.82,1.15,PCV15 (medium dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,1,1.33,1.67,1.07,PCV15 (medium dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,3,0.53,0.67,0.42,PCV13,1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,22F,0.05,0.06,0.05,PCV13,1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,19A,1.47,1.82,1.18,PCV15 (medium dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,14,4.24,5.42,3.31,PCV15 (medium dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,22F,4.34,5.55,3.4,PCV15 (medium dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,6B,1.62,2.61,1.01,PCV13,1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,4,1.31,1.64,1.05,PCV15 (high dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,5,1.36,1.98,0.94,PCV13,1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,7F,2.23,2.81,1.77,PCV15 (medium dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,4,1.14,1.45,0.89,PCV13,1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,18C,0.96,1.31,0.71,PCV15 (medium dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,19A,1.43,1.72,1.19,PCV15 (high dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,7F,2.87,3.37,2.44,PCV15 (high dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,5,1.13,1.55,0.83,PCV15 (high dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,1,1.49,1.87,1.19,PCV15 (high dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,6A,2.82,4.12,1.93,PCV13,1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,6A,1.41,2.1,0.95,PCV15 (medium dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,22F,4.79,5.91,3.88,PCV15 (high dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,9V,1.44,1.97,1.05,PCV15 (high dose),1m post boost child,3+1 child,64
NCT02531373,Merck Sharp & Dohme LLC,"Phase 1, Phase 2",,"[""Child"",""Adult""]",1 month after Vaccination 3 (Month 5),IgG,4,4,1.46,1.77,1.2,PCV15 (medium dose),1m post boost child,3+1 child,64
